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Abstract 
Pulmonary Arterial hypertension (PAH) is a rare and progressive condition presenting with 
exercise intolerance, leading to right ventricle (RV) failure and death. There has been 
significant progress in understanding the basic pathophysiology leading to the development of 
a number of targeted therapies, resulting in improved prognosis. Despite this, patients remain 
limited in performing exertional activities with a poorer quality of life. Recent research has 
focused on PAH being a multi-systemic disease with skeletal muscle dysfunction contributing 
to exercise intolerance.  There needs to be greater understanding of the physiological and 
behavioural mechanisms that limit daily functional capabilities in PAH patients.  
The aims of the thesis were to study the role of skeletal muscle mitochondrial function, the 
limitations in central and peripheral haemodynamics on maximum exercise, and develop a 
greater understanding of whether habitual daily physical activity levels are improved by 
current pharmaceutical treatments.  
Using 31Phosphorous-magnetic resonance spectroscopy (31P-MRS), oxygen delivery as 
opposed to impaired mitochondrial function would explain the abnormal skeletal muscle 
bioenergetics observed. This is further supported by analysing skeletal muscle biopsy samples 
demonstrating that mitochondrial protein expression and function was normal, therefore not 
contributing to impaired exercise capacity. Using continuous non-invasive cardiac output, 
chronotropic incompetence and reduced peripheral oxygen extraction are the predominant 
mechanisms leading to impaired peak oxygen consumption. Finally, in a pilot study targeted-
therapies failed to change habitual daily physical activity and fatigue levels in PAH patients 
despite a significant observed change in submaximal exercise capacity.   
In conclusion, a number of physiological mechanisms that impair exercise capacity and 
habitual physical activity in PAH are beyond the currently available targeted therapies. 
Further research is needed into how best to improve exercise capacity, fatigue and activity 
levels that will directly lead to improvement in quality of life for PAH patients. 
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Chapter 1 Introduction 
1.1 Pulmonary Hypertension 
1.1.1 Definition 
Pulmonary hypertension (PH) is a disorder that can affect cardiac and respiratory diseases, 
afflicting the pulmonary vessels, leading to impaired right ventricle (RV) function and early 
death without appropriate treatment. (Humbert et al., 2014) Patients suffer from insidious 
onset of breathlessness, fatigue, syncope and sudden death. The underlying aetiology leading 
to the development of PH guides the treatment and prognosis.  Since the 1990s a number of 
successful therapies that have been developed for the treatment of specific types of PH, with 
the availability of surgical options including lung or heart-lung transplantation as a final 
treatment strategy. (Simonneau et al., 2016) Although the survival of patients with PH has 
improved, the disease remains incurable with patients living with a poor quality of life.  
1.1.2 Causes and Classification 
Since the first World Symposium on Pulmonary Hypertension (WSPH) in 1973 in Geneva, 
Switzerland, the classification system has been in place to facilitate a common diagnostic and 
treatment approach. This system continued to undergo modifications at subsequent WSPH 
symposiums held every five years, with the current classification being in place from the 
meeting held in Nice 2013 (Figure 1). (Simonneau et al., 2013)  
Pulmonary Arterial Hypertension (PAH) makes up group 1 of the classification system and so 
far, has been the group which has shown significant beneficial outcomes from targeted 
therapies.  
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Figure 1: Updated Classification System of Pulmonary Hypertension     
 Reproduced from (Simonneau et al., 2013) 
 
 
1. Pulmonary Arterial Hypertension 
1.1 Idiopathic 
1.2 Heritable 
1.2.1 BMPR2 
1.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK3 
1.2.3 Unknown 
1.3 Drug and toxin induced 
1.4 Associated with 
1.4.1 Connective tissue disease 
1.4.2 HIV infection 
1.4.3 Portal Hypertension 
1.4.4 Congenital heart diseases 
1.4.5 Schistosomiasis 
1’ Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis 
1’’ Persistent pulmonary hypertension of the newborn (PPHN) 
2. Pulmonary hypertension due to left heart disease 
2.1 Left ventricular systolic dysfunction 
2.2 Left ventricular diastolic dysfunction 
2.3 Valvular disease 
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital 
cardiomyopathies 
3. Pulmonary hypertension due to lung diseases and/or hypoxia 
3.1 Chronic obstructive pulmonary disease 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4 Sleep-disordered breathing 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitude  
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
5.1 Hematologic disorders: chronic haemolytic anaemia, myeloproliferative 
disorders, splenectomy 
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, 
lymphangioleiomyomatosis 
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid 
disorders 
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, 
segmental PH 
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1.2 Pulmonary Arterial Hypertension 
1.2.1 Epidemiology 
Pulmonary arterial hypertension (PAH) is rare disease with a low incidence and prevalence.  
The major national published registries report an incidence per million of PAH between 2.0-
7.6 cases with prevalence of 10.6-26 cases per million. (Hoeper et al., 2013a) The mean age 
of diagnosis has moved away from average of 36 ± 15years in 1987, to between 50 ± 14 and 
65 ± 15 years in the last 10 years. (Rich et al., 1987, Badesch et al., 2010, Hoeper et al., 
2013b) Females make up 65-80% of patients. (Humbert et al., 2006, Benza et al., 2010) 
1.2.2 Prognosis 
Prognosis can be determined by clinical characteristics including underlying aetiology, age, 
World Health Organization (WHO) functional class, cardiopulmonary haemodynamics and 
exercise capacity. (McLaughlin et al., 2004) More pertinently, how the right ventricle 
responds to the increased afterload at rest and on physical exertion has gained significant 
importance in determining prognosis in recent years. (Naeije and Manes, 2014) In the early 
1990s, median reported survival of PAH patients was 2.8 years, and a 5- year survival rate of 
34%. (D'Alonzo et al., 1991) The advent of increased number of PAH-targeted therapies, has 
led to improved survival with a reported 1, 3 and 5-year survival rate are approximately 84%, 
67% and 58%, respectively. (Thenappan et al., 2010) 
1.2.3 Pathophysiology 
PAH pathophysiology understanding has increased considerably in the last 30 years. The 
pulmonary vessels are normally under low-pressure with approximately one-tenth of the 
resistance to blood flow when compared to the systemic circulation. (McLaughlin and 
McGoon, 2006) There are number of different molecular and cellular mechanisms that play a 
vital role in progressive pulmonary vasculopathy leading to vasoconstriction, cell 
proliferation, and in-situ thrombosis. (Humbert et al., 2014) 
There are three main cellular pathways identified, leading to the development of targeted 
therapies. The first is prostacyclin which has vasodilating and antiproliferative actions in 
pulmonary vessels. (Jones et al., 1989) In PAH patients, prostacyclin synthetase activity is 
reduced therefore prostacyclin (PGI2) levels are reduced. (Tuder et al., 1999) Endothelin -1 
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levels are elevated in PH. (Giaid et al., 1993) The second is endothelin-1(ET-1) which has 
both vasoconstrictive and proliferative function, by acting on two receptors, ETA and ETB. 
Prognosis of PAH patients has been correlated with ET-1 levels. (Rubens et al., 2001) The 
third is nitric oxide (NO) which leads to vasodilation. In PAH there is decreased NO synthase 
expression leading to vasoconstriction. (Giaid and Saleh, 1995) There are other mechanisms 
involved, including mitochondrial dysfunction, role of voltage-dependent potassium channels, 
activation of the coagulation cascade, platelet and endothelial cell dysfunction. (Archer et al., 
2008)  
The general understanding of the pathophysiology of PAH has advanced most recently as the 
ability to sequence genes has improved. Mutations in bone morphogenetic protein receptor II 
(BMPRII) leads to lack of apoptosis and uncontrolled cellular proliferation in pulmonary 
vessels. This is the most common mutation causing familial PAH, responsible for 60-80% 
cases. (Newman et al., 2001) The mutation is also found in 20% of patients with sporadic 
idiopathic PAH.  Other genetic, rarer alterations have been discovered including ALK-1, 
SMAD9, KCNK3, endoglin and caveolin-1. (Tuder et al., 2013). 
The concept of “multiple-hits” hypothesis has been proposed whereby a genetic substrate with 
a mutation or polymorphism being present with an environmental stimulus of unknown origin 
leads to the development of PAH. (McLaughlin and McGoon, 2006, Machado et al., 2005, 
Yuan and Rubin, 2005) 
1.2.4 Diagnosis 
The diagnostic process in any patient suspected of PAH consists of the basics including 
careful history and examination, and then followed by screening transthoracic 
echocardiography. The gold-standard of haemodynamic measurement is by right heart 
catheterisation, carried out for accurate diagnosis, assess the severity and then decide on 
appropriate treatment. (McLaughlin and McGoon, 2006) An overview of the clinical 
diagnosis process will now be briefly described.  
1.2.4.1 History and examination 
Patients typically report shortness of breath, fatigue, syncopal episodes and peripheral 
oedema. History should be focused on finding and excluding potential risk factors for PAH. 
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Clinical examination to find features of the underlying cause of PH, including those of portal 
hypertension,human,  immunodeficiency virus (HIV) and connective tissue disease. There 
may be clinical signs of right ventricle failure including peripheral oedema, abdominal 
distension and raised jugular venous pressure. (Galie et al., 2016) 
1.2.4.2 Clinical Investigations 
Baseline pathology tests are undertaken to assess haematology and biochemistry functions. At 
the same time, testing of thyroid function, autoantibodies, blood-borne viruses including HIV, 
hepatitis B and C are carried out. The severity of right heart dysfunction can be assessed by 
measuring N-terminal prohormone brain naturietic peptide (NT-proBNP) and is an 
independent predictor of outcome. (Galie et al., 2016). Pulmonary function tests and arterial 
blood gases allow for further assessment of any underlying airway or interstitial lung disease. 
(Trip et al., 2013, Sun et al., 2003)  
Electrocardiogram features in PAH may show right-axis deviation, right ventricular 
hypertrophy, with ST- and T- abnormality with inversion to suggest right ventricular strain. 
(Henkens et al., 2008, McLaughlin and McGoon, 2006) 
Transthoracic echocardiogram (TTE) is a commonly used tool to evaluate patients for the 
potential diagnosis of PH by assessing the effect on RV function and estimating pulmonary 
arterial pressure (PAP) by doppler measurements. There is a strong correlation between right 
ventricular systolic pressure estimated from the TTE to the mean pulmonary arterial pressure 
on invasive right catheter measurements. (Currie et al., 1985) Furthermore, TTE allows for 
assessment of the left ventricle size and function, including estimating the size of the left 
atrium to determine whether left heart disease is the cause of PH. (Howard et al., 2012) 
Apart from chest radiography, more detailed imaging is undertaken to determine the 
underlying aetiology of PH. This will include high resolution computer tomography or 
contrast-enhanced CT scan to look for features of interstitial lung disease, or alternative 
causes of PAH including the presence of oesophageal dilation in systemic sclerosis or 
vascular abnormalities due to congenital cardiac defects. (Rajaram et al., 2015) 
Computer tomography pulmonary angiogram and ventilation-perfusion (V/Q)scans are 
carried out to determine the presence of chronic thromboembolic disease, with V/Q having 
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higher sensitivity. Even without chronic thromboembolic disease, in PAH V/Q scan can 
demonstrate peripheral unmatched or non-segmental defects in perfusion. (Tunariu et al., 
2007, McLaughlin and McGoon, 2006)   
1.2.4.3 Right heart catheterisation  
The gold-standard method of diagnosing PAH is by right heart catheterisation (RHC) and 
allows for the assessment of the severity of cardiopulmonary haemodynamics. (Galie et al., 
2016) By international consensus, the haemdynamic definition of PAH is a mean pulmonary 
arterial pressure (mPAP) of ≥ 25mmHg, pulmonary capillary wedge pressure (PCWP) of 
≤15mmHg and pulmonary vascular resistance (PVR) of > 3 Wood units. (Hoeper et al., 
2013a) Furthermore, RHC can measure baseline resting cardiac output, thereby determining 
the impact of obstruction to blood flow on how well the right ventricle is functioning.(Hoeper 
et al., 1999) Vasoreactivity testing is undertaken in selected patients by using nitric oxide or 
prostacyclin analogues to determine if these patients drop their respective mPAP in response. 
If they do, these select patients are treated with calcium channel blockers as the first step. 
(Figure 2) (Benza et al., 2015) 
1.2.4.4 Exercise tests 
Exercise capacity can be determined by a number of different methods including the six-
minutes’ walk distance (6MWD) and symptom-limited cardiopulmonary exercise testing 
(CPEX) most commonly using a cycle ergometer. The absolute 6MWD achieved is affected 
by age, gender, co-morbidities, learning and motivation.(Galie et al., 2016) Baseline and 
follow-up absolute 6MWD has prognostic implications, with patients achieving less than 
150m having poorer outcome and those with values more than 380m have improved survival. 
(Sitbon et al., 2002, Barst et al., 1996, Miyamoto et al., 2000) The percentage change or 
absolute change in 6MWD has no prognostic implications. (Farber, 2012) 
CPEX as opposed to 6MWD, is performed to maximal exercise, allowing assessment of 
exercise capacity, gas exchange and cardiac function. CPEX testing has been shown to 
correlate to functional class but less well with baseline haemodynamics.(Sun et al., 2001) 
Maximal oxygen consumption of greater than > 10.1ml.kg-1.min-1 and peak systolic blood 
pressure > 120mmHg associated with improved survival. (Sun et al., 2001) 
7 
 
Exercise testing allows the clinicians to assess the functional impact of the disease on the 
individual basis. By following objective, standardised protocol the tests can be repeated when 
following up patients to determine the effect of treatment.  
1.2.5 Treatment 
Treatment for pulmonary arterial hypertension is determined by the classification system and 
approached according existing international guidelines. (Figure 2) (Galie et al., 2013) The 
majority of therapies has only been licenced for Group 1 disease. Chronic thromboembolic 
pulmonary hypertension (Group 4) should be assessed at a specialist centre performing 
pulmonary endarterectomy to determine if surgery would be beneficial. Recently, Riociguat 
(soluble guanylate cyclase inhibitor) has been licenced for patients with  inoperable or distal 
CTEPH.(Ghofrani et al., 2013) 
Patients are provided with general lifestyle advice. These include provision of low graded 
aerobic exercise, avoiding exposure to high altitudes, need for some patients to have inflight 
oxygen, and avoidance of pregnancy. (Badesch et al., 2004)  
Conventional treatment in all patients should include the provision of diuretics to manage 
fluid status, maintaining oxygen levels above 90% to avoid hypoxic pulmonary 
vasoconstriction, and anticoagulation in certain groups including those with idiopathic, 
familial and anorexigen-induced PAH. (Olsson et al., 2014) 
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Figure 2: Current treatment algorithm from the 5th World Pulmonary Hypertension 
Symposium.  
APAH – associated pulmonary arterial hypertension; BAS – balloon atrial septostomy; CCB 
– calcium channel blockers; ERA – endothelin receptor antagonist; sGCS – soluble guanylate 
cyclase stimulators; IPAH – idiopathic pulmonary arterial hypertension; i.v – intravenous; 
PDE-5i – phosphodiesterase type 5 inhibitor; s.c – subcutaneous; WHO-FC – World Health 
Organization functional class. Figure reproduced from (Galie et al., 2013) 
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1.2.5.1 PAH -Targeted Treatment  
In the last two decades, a number of treatments have been approved that target specific 
pathways leading to PAH. All approved medications focus on the three main pathways 
described earlier and work by increasing nitric oxide production through inhibition of 
phosphodiesterase enzymes, blocking the action of endothelin at the receptor or as 
prostacyclin analogues. (Galie et al., 2013). The current treatment algorithm in treating PAH 
is shown in Figure 2. 
The current guidelines suggest the goal of treatment is to achieve a low-risk status in patients. 
(Galie et al., 2016) This would include achieving with appropriate treatment an exercise 
capacity (6MWD >440m), WHO functional class II, maintaining RV function and improving 
quality of life. This may require escalation of treatment from single to combination targeted 
therapy if these goals are not met. If the patient’s functional level is poor at diagnosis than 
this may require continuous prostacyclin analogues, upfront combination treatment or triple 
therapy. (Sitbon et al., 2014, Galie et al., 2015) 
1.2.5.2 Atrial Septostomy  
Atrial septostomy is used for palliation or as a bridge to transplantation. This procedure 
results in a right to left interatrial shunt,  increasing the cardiac output, decreasing the 
pulmonary arterial pressure and ultimately increasing systemic oxygen transport despite a fall 
in oxygen saturations. (Sandoval et al., 1998) 
1.2.5.3 Lung Transplantation 
Lung transplantation is an accepted management strategy in selected patients with 
progressive PAH where medical options have been exhausted as determined by international 
consensus. (Galie et al., 2013) Most PAH patients on the waiting list undergo double-lung 
transplantation apart from patients with complex congenital heart disease who may receive 
heart-lung transplantation. Among all indications for lung transplantation, PAH patients have 
the highest 3-month and 1-year mortality. If survival is achieved beyond the first year, the 
median survival time is 9.3years. (George et al., 2011) 
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1.3 Pathophysiology of Exercise Limitation 
1.3.1 Mechanisms of exercise 
Exercise intolerance is a predominant complaint afflicting patients with cardiovascular, 
pulmonary, or musculoskeletal conditions. Patients with PAH report symptoms of shortness 
of breath and musculoskeletal fatigue on exertion. (Sun et al., 2001) This leads to an inability 
to perform daily activities including those required to maintain employment and the basic 
necessities of daily living leading to poorer quality of life. (Flattery et al., 2005) Addressing 
the factors causing exercise intolerance has always been the focus of treatment for both 
symptom control and improving prognosis in diseases causing diminished exercise capacity. 
Further, pathology affecting one system commonly has sequelae on other body systems. As a 
result, each individual patient has multifactorial causes for their exercise intolerance and 
fatigue. Skeletal muscle is commonly recognised to be affected by cardiopulmonary 
conditions including chronic obstructive pulmonary disease (COPD) and left heart failure. 
(Gea et al., 2016, Kennel et al., 2015)  
1.3.2 Mechanisms affecting exercise capacity in PAH 
1.3.2.1 Introduction 
There are multiple mechanisms that are now recognised contributing to impaired exercise 
capacity in PAH affecting the pulmonary, cardiovascular and musculoskeletal systems. The 
changes in skeletal muscle in PAH are discussed later in the chapter. An overview of the 
mechanisms of exercise intolerance in PAH will be described below.  
1.3.2.2 Right ventricle function in PAH 
The resistance to blood flow in the pulmonary vessels is increased due to impaired 
vasodilation, vasculopathy and remodelling. (McLaughlin and McGoon, 2006) The 
pulmonary vessels demonstrate reduced distensibility and progressive increase in resistance. 
(Vonk Noordegraaf and Galie, 2011)  The right ventricle pumps the same volume of blood as 
the left ventricle against low resistance, high capacitance pulmonary vessels.  The RV is 
much more compliant than the left ventricle (LV) and able to adapt to the increased afterload 
in PAH. Therefore, in early development of PAH, RV contractility increases and cardiac 
index is maintained. (Vonk Noordegraaf and Galie, 2011) 
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As the pulmonary vascular resistance increases, RV undergoes hypertrophy, remodelling and 
eventually dilation. (Benza et al., 2015) In most patients with PAH, cardiac index is reduced 
at diagnosis. (Benza et al., 2010) The response and changes in the RV to the increased 
hydraulic afterload is very patient specific. The reduced RV contractility and impaired RV – 
pulmonary artery coupling seen in PAH patients is important to the overall outcome and 
prognosis of the patient. (van Wolferen et al., 2007, Grapsa et al., 2015, Raymond et al., 
2002) 
The increase in RV end-systolic and end-diastolic volumes affects the left ventricle function 
during the cardiac cycle due to the shift in the interventricular septum to the left and reducing 
LV preload. (Gan et al., 2006) There is additional evidence cardiomyocyte atrophy within the 
LV occurring in patients with PAH. (Manders et al., 2014) This leads to decreased LV 
function, with evidence of reduced LV contractility, and acting as another factor impairing 
systemic oxygen delivery. (Benza et al., 2015) 
During exercise, patients with PAH have an impaired ability to augment stroke volume 
(Holverda et al., 2006) and chronotropic incompetence.(Sun et al., 2001) The diminished 
ability to increase stroke volume and heart rate reduces the cardiac output during exercise.  
The currently available targeted treatments for PAH acts by pulmonary artery vasodilation. 
The decreased afterload leads to increased cardiac output at rest. (Kuhn et al., 2004, 
Sasayama et al., 2005) The effect of treatment on maximum exercise performance leads to 
increased oxygen consumption with some limited evidence of improvement in exertional 
cardiac output. (Arena, 2011, Provencher et al., 2008) 
The right ventricle function and cardiac output in PAH can be assessed using non-invasive 
and invasive methods. These include transthoracic echocardiography, cardiac magnetic 
resonance imaging, and right heart catheterisation. All three methods are used at the 
diagnostic stage to evaluate patients depending on availability at individual centres.   
1.3.2.3 Respiratory impairment in PAH 
There are pulmonary factors contributing to reduced exercise intolerance. There is evidence 
of respiratory muscle weakness in PAH including diaphragmatic involvement affecting 
alveolar ventilation. (Panagiotou et al., 2015) The reduced transfer factor of carbon monoxide 
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(TLCO) is due to the pulmonary membrane diffusing capacity, ventilation/perfusion 
mismatch and rapid red cell transit time leading to hypoxaemia. (Fowler et al., 2012) 
(Chandra et al., 2010)  
1.3.2.4 Extrasystematic features in PAH 
PAH is recognised as a disease that affects other organs in the body. (Figure 3) There are 
factors beyond the cardiopulmonary systems contributing to exercise intolerance in PAH. 
Iron deficiency is common in PAH and may contribute to the pulmonary vasculopathy. 
(Rhodes et al., 2011) Iron supplementation resulted in improvement in exercise endurance 
and aerobic capacity in PAH. (Ruiter et al., 2015) Increasing accumulation of evidence 
suggests skeletal muscle dysfunction in PAH could also be contributing to exercise 
intolerance and this will be discussed later on in the chapter. (Manders et al., 2015)  
Figure 3:  Beyond the resistance in pulmonary arteries, other organs are involved in 
PAH.  
There is remodelling of the pulmonary arteries and right ventricle. Immune cells that are 
activated in the bone marrow are found in the lung parenchyma contributing to the pathology. 
There are metabolic changes in the skeletal muscle including the presence of lipid droplets 
suggesting evidence of insulin resistance. Reprinted from (Paulin and Michelakis, 2014) 
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1.3.3 Peripheral oxygen extraction 
Exercise capacity can be assessed using submaximal testing (eg 6MWD) or maximal testing 
in particular CPEX. The use of CPEX allows for an integrative assessment of cardiac, 
pulmonary and skeletal function of the patient. (Wasserman et al., 2005) The oxygen 
consumption (VO2) is an assessment of cardiac output (CO) and the difference arterial-
venous oxygen difference (AVO2 diff) – Fick principle. (Wasserman et al., 2005) 
VO2 = CO × AVO2 diff 
From the equation above, not only is exercise capacity is dependent on cardiac output but 
also on the ability of the peripheral tissues to extract oxygen from the blood. AVO2 diff is the 
difference in oxygen content between the arterial supply to the tissues and the mixed venous 
return to the right heart taking into account haemoglobin, oxygen saturation and the partial 
pressure of oxygen. Oxygen content at any one point in the blood supply system can be 
calculated by the following equation. (Finch and Lenfant, 1972) 
Oxygen content (mL/dL) = (Haemoglobin × 1.39 × O2 saturation) + (0.003 × partial 
pressure O2) 
Therefore the relative values in the arterial and venous system can be assessed to calculate 
the peripheral oxygen extraction. During peak exercise, we can assume the majority of the 
blood supply is diverted to the working skeletal muscle. Therefore, assumption is made that 
AVO2 diff is a reflection on the peripheral oxygen extraction of skeletal muscle. At rest the 
normal AVO2 diff is 5mL/dL and at peak exercise about 15mL/dL in a healthy patient based 
on haemoglobin of 15 g/dL. (Beck et al., 2006) Normally, the average AVO2 diff is equal to 
the haemoglobin value of the individual. (Dhakal et al., 2015) 
 There are four steps that are involved in the transport of oxygen to the tissues: 1) ventilation 
2) diffusion into the lungs 3) perfusion (convection) and 4) diffusion into the tissues. 
(Wagner, 1996) Loss of function in any one of the components causes significant impact on 
oxygen consumption. The diffusion and utilization of oxygen into the skeletal muscle is 
dependent on a number of factors. These include local sympathetic function, vasodilatory 
capacity of the small resistance vessels and microvascular control mechanisms to match 
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oxygen supply to demand. (Dhakal et al., 2015) In chronic heart failure, there is evidence of 
reduced muscle blood flow despite adequate arterial blood pressure, leading to increased 
oxygen extraction but reduced utilization, thus resulting early anaerobic metabolism. 
(Sullivan et al., 1989) In patients with heart failure with preserved ejection fraction, 
peripheral oxygen extraction has been shown to be reduced and markedly contributing to 
impaired oxygen consumption during upright exercise testing. (Dhakal et al., 2015) A 
potential mechanism discussed is that diffusion rather than convection of oxygen had the 
greatest impact on the reduced exercise capacity in these patients. These studies show that 
consideration of peripheral oxygen extraction as part of exercise capacity is an important part 
of the integrative assessment of the mechanism that underlie exercise limitation.  
1.3.4 Measuring components of oxygen consumption 
Oxygen consumption is measured using breath by breath gas analyser during physical 
exertion either on a treadmill or cycle ergometer. Cardiopulmonary exercise testing is an 
established and validated method of assessing cardiopulmonary function in both healthy and 
disease patients. (Wasserman et al., 2005) The components of VO2 can be assessed by 
invasive and non-invasive methods.  
Invasive methods include the placement of radial and pulmonary artery catheter into the 
patient prior to exercising. This allows for sampling of the arterial and mixed bloods on a 
minute by minute basis allowing for the cardiac output can be calculated using the Fick 
principle. (Maron et al., 2013) Furthermore, it allows continuous assessment arterial blood 
pressure and pulmonary artery pressures changes. However, this method is hampered by the 
invasive nature leading potential problems in recruitment, complications and resource 
intensive. (Maron et al., 2013) 
Non-invasive methods of assessing cardiac output are now available that can be performed 
during CPEX testing. (Jones et al., 2015) Therefore, AVO2 diff can be calculated from the 
Fick equation. This has the advantageous of being non-invasive without the associated 
complications and resources needed. There are number of methods of assessing cardiac 
output including doppler echocardiography, inert gas rebreathing technique, electrical 
impedance, and pulse contour analysis (Siebenmann et al., 2015)  A number of these methods 
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due to the non-invasive nature have inherent problems with accuracy and reliability. 
(Warburton et al., 1999) 
Bioreactance is a non-invasive method of continuously measuring cardiac output that has 
been to be accurate, reliable and reproducible on exercise. (Jones et al., 2015) Bioreactance 
works by measuring the frequency in the phase shift of transthoracic electrical currents as a 
reflection of blood flow to determine cardiac output. (Keren et al., 2007) Bioreactance has 
been studied in PAH patients in comparison to thermodilution and Fick methods, and has 
been shown to be accurate, comparative to Fick’s method and responsive to treatment. (Rich 
et al., 2013) Furthermore, bioreactance has been used in other pathologies to demonstrate 
impaired peripheral oxygen extraction as contributing to impaired exercise capacity. 
(Jakovljevic et al., 2012b) Bioreactance is an accepted validated non-invasive technology to 
accurately measure cardiac output at rest and on exercise. (Jones et al., 2015) 
1.3.5 Exercise training in PH 
Despite optimised drug based therapies, most patients remain symptomatic with a low quality 
of life.  Prior to 2006, the impact of lifestyle changes particularly exercise was thought to 
have a negative impact that may contribute to the progression of PH and harmful to patients. 
Exercise training and rehabilitation have been utilised in other cardiac and pulmonary disease 
in the last two decades to improve symptom control and physical functioning with beneficial 
outcomes, that has been proven repeatedly in randomized controlled and meta-analysis 
studies. (van Tol et al., 2006, de Blasio and Polverino, 2012) Exercise training in PH in both 
animal and human studies has yielded positive outcomes leading to improved exercise 
capacity. The current guidelines recommend strongly of the benefits of supervised graded 
aerobic exercise training. (Galie et al., 2013) 
Preclinical animal studies using both chronic hypoxia and monocrotaline-induced PH rats 
demonstrated that exercise training led to a number of benefits. First of all, they demonstrated 
a lack of pulmonary vasoreactivity alterations to exercise. (Goret et al., 2005) This was 
followed by improved exercise endurance, capillary density within the myocardium and 
promoting positive changes in the right ventricle and pulmonary artery remodelling. 
(Handoko et al., 2009, Colombo et al., 2013) 
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A seminal paper by Mereles et al 2006, using a supervised aerobic exercise programme first 
showed the additional benefit of exercise in terms of cardiopulmonary fitness and quality of 
life. (Mereles et al., 2006)  The exercise prescription involved 3 weeks inpatient stay with 
skeletal and respiratory muscle training. Aerobic training consisted of interval cycle 
ergometer at moderate heart-rate intensity which was followed by another 12 weeks of home 
exercise programme  predominantly involving the use of bicycle ergometer as set by the 
researchers for each patient. On follow up assessment compared to the control group they 
found improvement in 6MWD, quality of life scores, WHO functional class, peak oxygen 
consumption, anaerobic threshold and achieved workload. The study reported no adverse 
effects. 
Since then several studies have reinforced and supported aerobic exercise training as a 
beneficial therapy in patients with PH of different causes with improvement in 6MWD, WHO 
functional class, and peak oxygen consumption. (Handoko et al., 2009, Grunig et al., 2011, 
Grunig et al., 2012a)  More pertinently, the studies have repeatedly shown that moderate 
intensity exercise is safe in this patient population group contradicting previously accepted 
views that exercise was unsafe in PH patients. (Grunig et al., 2012a)  
A recent polled meta-analysis and systematic review of the available exercise training studies 
in PH including observational and controlled studies revealed a number of positive outcomes 
for patients. This included a significant increase in 6MWD of 62m (95% CI: 45 -78) at 12 
weeks of exercise that can be considered clinically significant. Furthermore, CPEX testing 
demonstrated improvement in peak oxygen consumption and workload both at 3 and 12/15 
weeks after training. Quality of life measured using SF-36 score improved in the areas of 
physical, social and emotional functioning. There was no alteration in body pain, general 
health or mental health scores. (Yuan et al., 2015)  
The studies have shown limited correlation between improved cardiopulmonary fitness and 
quality of life scores with cardiovascular haemodynamic values as assessed by transthoracic 
echocardiography. (Mereles et al., 2006) The benefits of exercise as an add-on therapy has 
been proven in PH of different causes including connective tissue disease (CTD), congenital 
heart disease (CHD) and inoperable chronic thromboembolic pulmonary hypertension 
(CTEPH) group. (Grunig et al., 2012b, Nagel et al., 2012, Becker-Grunig et al., 2012) 
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1.3.6 Summary  
PAH is a disease that impacts multiple systems. As a result the symptoms the patients 
experience cannot be addressed by targeting treatments on any one system. The remarkable 
benefits shown by exercise training beyond optimized drug therapy, suggest further 
understanding of the pathophysiological changes that occurs within the skeletal muscle is 
warranted. An overview of skeletal muscle structure and function will now be discussed. 
1.4 Skeletal Muscle Structure and Function 
1.4.1 Introduction 
Skeletal muscle in humans comprises 40% of body weight, with up to 75% of body proteins 
and encompassing maximum of 50% of body protein turnover. (Frontera and Ochala, 2015) 
The structure of muscle consists of highly arranged muscle fibres with associated connective 
tissue. Muscle size is due to the number and size of muscle fibres. They contribute to multiple 
bodily functions including converting chemical to mechanical energy to generate power that 
contributes to movement and activity, functional independence and enhancing health. The 
two main properties of skeletal muscle are to provide strength and endurance. (Frontera and 
Ochala, 2015) 
1.4.2 Extracellular matrix 
The epimysium is a layer of connective tissue surrounding individual muscle and is 
continuous with the outer layer of the tendon. Within the muscle, group of fibres are arranged 
in parallel bundles and surrounded by the perimysium. Each muscle fibre is approximately 
1cm in length and 100µm in diameter. (Ganong, 2003, Gillies and Lieber, 2011) Muscle 
fibres are surrounded by the sarcolemma otherwise known as the cell membrane. The 
sarcolemma consists of the basement membrane and plasmalemma. The basement membrane 
consists of a glycoprotein complex involved in the organization of neuromuscular junction, 
termination of synaptic transmission and connecting the endomysium with the plasmalemma. 
(Borg and Caulfield, 1980, Passerieux et al., 2006) 
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1.4.3 Muscle fibre ultrastructure 
Each muscle fibre is a multinucleated single cell with a cylindrical structure. The muscle 
fibre is made of multiple myofibrils, each made of individual filaments. The filaments are 
made up of contractile proteins. (Figure 4) The muscle proteins make up the contractile 
mechanism in the skeletal muscle and these include actin, myosin-II tropomyosin and 
troponin. Troponin is consists of three subunits that are troponin I, troponin T and troponin C. 
(Ganong, 2003) 
The classical cross-striations seen in skeletal muscle can be seen Figure 4. Between two 
adjacent Z lines is an area call the sarcomere. The thick filaments consists of myosin forming  
the A band. The thin filaments consisting of actin, tropomyosin, and troponin make up the 
less dense I bands. The Z line transects the fibrils that connect the thin filaments. (Ganong, 
2003) 
Figure 4: The gross muscle ultrastructure, the relationship of between the myofibrils, 
mitochondria and the connective tissue. 
(Reproduced from https://courses.candelalearning.com/ap2x1/chapter/skeletal-muscle/)  
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Myosin-II has two heads and a long tail, forming cross-links to actin. Myosin heads contains 
two important areas, an actin binding site and the area where adenosine triphosphate (ATP) is 
hydrolysed. The thin filaments consist of two chains of actin in double helix pattern. 
Tropomyosins are located in the grove of the double helix, the troponin located at set 
intervals along the tropomyosin. Troponin T binds the entire troponin structure to 
tropomyosin.  Troponin I role is to inhibit the interaction of myosin with actin whereas 
troponin C is where calcium binds for the initiation of contraction. (Frontera and Ochala, 
2015)  
There are further three more important muscle proteins: actinin binds actin to the Z lines, titin 
links the Z line to the M line and desmin binds the Z lines to the plasma membrane. The 
sarcotubular system, consists of the T system which are transverse tubules forming a grid 
around the muscle fibrils and sarcoplasmic reticulum around each of muscle fibrils. The 
sarcoplasmic reticulum has a fundamental role in the movement of calcium. (Ganong, 2003) 
The transmission of action potential is via the T system. The mechanism of muscle 
contraction will now be discussed.  
1.4.4 Muscle contraction 
The depolarization of the muscle fibre leads to contraction and this process is called the 
excitation-contraction coupling. The motor end-plate is the starting point of muscle fibre 
membrane depolarization. The action potential is transmitted to the muscle fibre leading to 
muscle contraction. A muscle twitch is the result of a single action potential leading to 
contraction and then relaxation. The length of muscle twitch differs depending on the type of 
muscle fibre. (Allen et al., 2008) 
Prolonged action potential leads to muscle contraction by the movement of the thin filaments 
over the thick filaments. The Z lines move closer together during contraction. The sliding 
action is the result of the myosin heads binding to actin, bending at the neck and then 
detaching. (Calderón et al., 2014) This repeated action leads to the sliding movement. This 
bending action of the myosin-II molecules depends on the hydrolysis of . Each so called 
“power stroke” shortens the sarcomere by 10nm. (Huxley and Niedergerke, 1954) 
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The T-tubules transmits the action potential to all the muscle fibrils, leading to the release of 
calcium from the terminal cisterns. (Bezanilla et al., 1972) The calcium binds to troponin C, 
leading to weakened attachment of troponin I to actin, tropomyosin moving away and 
exposing the binding sites for the myosin heads on actin. (Dulhunty, 2006, Ganong, 2003) 
The calcium diffuses back from the sarcoplasmic reticulum into the terminal cisterns for the 
next muscle contraction. The muscle then relaxes once the calcium concentration outside the 
sarcoplasmic reticulum goes below a threshold value. (Dulhunty, 2006) 
T tubule depolarization leads to sarcoplasmic reticulum activation through the 
dihydropyridine receptors (voltage-gated calcium channels), that act as a voltage sensor and 
triggers the release of calcium from the sarcoplasmic reticulum. (Santulli and Marks, 2015) 
The ryanodine receptor (non-voltage gated calcium channel) is located on the sarcoplasmic 
reticulum and is responsible for calcium release. The calcium – magnesium-ATPase moves 
calcium back into the reticulum, leading to muscle relaxation. (Allen et al., 2008, Ganong, 
2003) 
1.4.5 Muscle fibre types 
Skeletal muscle fibres vary in terms of their myosin ATPase activity, speed of contraction, 
fatigue resistance, glycolytic and oxidative capacity. (Engel, 1998) Generally, in simplistic 
classification, they are divided into type I and II.  The slow, oxidative  type I fibres  have a 
high content of mitochondria, increased capillary density and myoglobin content as opposed 
to  type II fibres that are fast-acting, highly glycolytic,  low oxidative capacity and easily 
fatigable. (Brooke and Kaiser, 1970b, Brooke and Kaiser, 1970a) The latter, type II fibres, 
can be further subclassified into IIa, IIb and IIx fibres.  Many would now regard this as an 
overly simplistic classification based on histochemical analysis of muscle biopsies, and argue 
that there is a spectrum of muscle fibre types. (Saltin et al., 1977) 
1.4.6 Muscle metabolism 
Muscle contraction requires a large amount of energy to produce mechanical work. ATP in 
muscle can be generated from the metabolism of carbohydrate and lipids as well as organic 
phosphate compound, phosphocreatine (PCr). (Calderón et al., 2014) During muscle rest, PCr 
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stores are built by ATP donating phosphate molecule to creatine. During active muscle 
contraction, PCr donates the phosphate molecule to ADP to build up ATP. Skeletal muscle 
PCr stores provide the majority of the energy in the first few seconds of heavy exercise and 
are rapidly depleted. (Haseler et al., 1985, Kemps et al., 2010) 
Muscle uses free fatty acids (FFA) to generate energy at rest and during light exercise. 
Carbohydrates are used as exercise intensity increases due to FFA being unable to provide all 
the required energy. During adequate oxygen supply, breakdown glucose produces pyruvate 
entering the Kreb’s cycle, otherwise termed aerobic glycolysis. (Ganong, 2003) At times of 
inadequate oxygen supply, the pyruvate is reduced to lactate rather than entering the Kreb’s 
cycle, termed anaerobic glycolysis. The net production of energy via anaerobic metabolism is 
much smaller than by aerobic metabolism. (Allen et al., 2008, Putti et al., 2015) 
During heavy exertion, ATP is generated through breakdown of phosphocreatine and 
anaerobic glycolysis. Lactate accumulates in the muscle to the extent exceeding the buffer 
mechanism, and lead to enzyme-inhibition by depressing muscle pH. After exertion, extra 
oxygen is consumed to remove the lactate, replace oxygen to the myoglobin and generate 
ATP and PCr stores. This extra oxygen is called the oxygen debt. (Allen et al., 2008, Kemp et 
al., 2007)  
The changes that occur during exercise in the muscle, otherwise known as bioenergetics can 
be studied non-invasively using spectroscopy and will be discussed in greater detail later in 
the chapter. 
1.4.7 Muscle changes in PAH  
Exercise intolerance in PAH is deemed primarily due to haemodynamic impairment but 
cardiac output is only partially correlated with exercise capacity. (Mainguy et al., 2010) 
During cardiopulmonary exercise testing, patients report leg fatigue and dyspnoea as being 
the common symptoms leading to the cessation of exercise, suggesting the existence of 
dysfunction within the peripheral skeletal muscles. (Sun et al., 2001) There is significant 
evidence from other cardiopulmonary diseases of skeletal muscle impairment including in 
chronic obstructive pulmonary disease and left ventricle systolic failure. (Kim et al., 2008, 
Piepoli and Crisafulli, 2014) 
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Meyer et al, proceeded to demonstrate weakness in both inspiratory and expiratory muscle 
function in patients with IPAH. They demonstrated in IPAH patients compared to control 
populations, that the maximum inspiratory (PI, max) and expiratory (PE, max) pressures 
generated was lower. There was no correlation between the respiratory muscle function and 
pulmonary haemodynamics. (Meyer et al., 2005) Building on this work, Bauer et al, showed 
forearm grip strength correlates with maximal inspiratory and expiratory mouth pressures but 
not with systolic pulmonary artery pressure. This lends further support to the notion and 
enhancing the concept of a generalised muscle weakness in PAH patients independent of 
cardiopulmonary haemodynamic severity. (Bauer et al., 2007) 
Quadricep non-volitional muscle strength correlates with exercise capacity. Skeletal muscle 
biopsies demonstrate change in muscle fibre type, with lower proportion of type 1 and 
increased type 2 fibres. There was evidence of higher potential for anaerobic than aerobic 
metabolism. More revealing was the presence of association between exercise capacity and 
muscle biopsy findings including two oxidative enzymes, citrate synthase and 2-hydroxyacyl-
CoA-dehydrogenase and capillary to type 1 fibre ratio. (Mainguy et al., 2010)  
In animal-models with PH induced by the injection of monocrotaline, the twitch and maximal 
tetanic force generation of the diaphragm muscle was weaker than control animals with a 
decrease in cross-sectional area (CSA) of muscle fibres. (Manders et al., 2012, de Man et al., 
2011) Possible mechanisms suggested were activation of the ubiquitin-proteasome pathway 
(UPS) with activation of the E3 ligases, atrogin-1 (MAFbx-1) and muscle ringer protein 1 
(MURF-1). Their work lends strong support to the role of impaired diaphragm contractility in 
PH patients contributing to exercise intolerance. 
There is evidence from skeletal muscle biopsies of IPAH patients of decreased Akt 
activation, with increased atrogin-1 expression and MURF-1 activity. (Batt et al., 2014) This 
suggests the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway function is 
impaired. This ultimately leads to the activation of the UPS system resulting in muscle 
breakdown and wasting, with downregulation of pathways that would stimulate muscle 
hypertrophy. (Batt et al., 2014) The work of this author supports existing evidence of skeletal 
muscle atrophy and weakening of the peripheral muscles compared to healthy controls. 
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The animal and human studies on the skeletal muscle so far have suggested PAH affects the 
individual patient beyond the function of the RV and pulmonary vessels. They have shown 
potential mechanisms affecting skeletal muscle function and contributing to the exercise 
intolerance experienced by patients.  
1.5 Mitochondria 
Mitochondria are cellular organelles involved primarily in energy metabolism. They create 
ATP from lipids and carbohydrates for cellular processes. Furthermore, they have a vital role 
in programmed cell death, redox haemostasis, calcium signalling and cellular metabolism. 
(Picard et al., 2011) Mitochondria within the lungs act as oxygen sensors by producing 
reactive oxygen species which control ion channels and enzymes. They are dynamic 
organelle capable of dividing (fission), joining together (fusion) and moving around the cell 
in networks. (Papa et al., 2012) Thus the accurate function of the mitochondria is crucial to 
the cell life and bodily functions.   
1.5.1 Structure and Function 
Mitochondria contain two membranes with the space in between termed the intermembrane 
space. The folded inner membrane form cristae and contains the oxidative phosphorylation 
system responsible for the generation of ATP. (Kayar et al., 1988) (Figure 5) 
The mitochondria contain maternally inherited DNA (mtDNA). The mitochondrial genome 
contains the coding for a number transfer (22) and ribosomal (2) RNAs as well as 13 subunits 
of the oxidative phosphorylation system. The nuclear genome encodes for the remaining 
proteins and subunits of the mitochondria. The nuclear DNA encoded proteins are produced  
in the cytoplasm and then moved to the mitochondria where the subunits are assembled into 
functional proteins. (Attardi and Schatz, 1988) 
1.5.2 Oxidative phosphorylation system (OXPHOS) 
The oxidative phosphorylation system (OXPHOS) is the main mechanism by which 
mitochondria generates ATP. The electron transport chain (ETC) contains five complexes (I-
V) including ATP synthetase on the inner mitochondrial membrane. (Figure 6) 
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Figure 5: Gross structure of the mitochondria 
 (From the US Genetics Library: https://ghr.nlm.nih.gov/) 
Kreb’s cycle otherwise known as the tricarboxylic acid cycle, is a series of reactions leading 
to the transfer of electrons to hydrogen from electron carriers. Therefore, it leads to the 
formation of nicotinamide adenine dinucleotide (NADH), hydrogen (H+) and flavin adenine 
dinucleotide (FADH2).  Acetyl-coenzyme A, the main intermediary product and a substrate 
for the Kreb’s cycle is generated by two pathways. Glucose is broken down to pyruvate by 
glycolysis in the cell cytoplasm and transported into the mitochondria by pyruvate 
dehydrogenase, where it is decarboxylated into acetyl-CoA.  Fatty acid is oxidized in the 
mitochondrial matrix to produce acetyl-CoA. (Papa et al., 2012) 
Complex I (NADH dehydrogenase) and complex II (succinate dehydrogenase) electrons are 
donated from NADH and FADH2 at the ETC. Coenzyme Q (ubiquinone) transfers electrons 
from complex I, II and dihydroorotate dehydrogenase to complex III (cytochrome c 
reductase). Then, complex III transfers the electrons to complex IV containing an electron 
acceptor. There is active pumping of electrons into the intermembrane space at complexes I, 
III and IV, leading to the development of the electrochemical gradient. (Schon et al., 2012) 
As a result, the gradient allows for the flow of electrons through complex V (ATP synthetase) 
into the mitochondrial matrix driving the production of ATP. (Papa et al., 2012) Each 
complex within the OXPHOS consists of multiple subunits with each one either be encoded 
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by nuclear or mitochondrial DNA. Some of the complexes consist of subunits entirely 
encoded by nuclear DNA only. (Schon et al., 2012) 
Figure 6: The respiratory chain of the OXPHOS system consisting of five complexes  
Complex I – NADH dehydrogenase, II – succinate dehydrogenase, III – cytochrome c 
reductase and IV – cytochrome c oxidase) and ATP synthase. CoQ- coenzyme Q, CytC – 
cytochrome c, e- - electron. All nuclear encoded subunits of the complexes are blue and 
mitochondrial encoded subunits are in alternative color. (Figure reprinted from (Schon et al., 
2012) 
1.5.3 Mitochondria in skeletal muscle 
In skeletal muscle, mitochondria are found in the intermyofibrillar (IMF, 80%) and 
subsarcolemmal (SS, 20%) regions. There are compositional, biochemical and functional 
differences between these two groups. Mitochondria located in the IMF have a higher rate of 
protein synthesis, higher complex IV and lower succinate dehydrogenase activity compared 
to subsarcolemmal mitochondria. (Cogswell et al., 1993) 
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1.5.4 Evidence of mitochondrial involvement in PAH 
Mitochondria are involved in cellular respiration and bioenergetics. They have a role in the 
signalling between pulmonary artery endothelial cells (PAEC) and pulmonary smooth muscle 
cells (PSMC). (Freund-Michel et al., 2014) Furthermore, mitochondria play a significant role 
in cell cycle regulation. In plexiform lesions that are pathognomonic feature of IPAH, 
apoptosis-impaired proliferation of PAECs/PSMCs has been observed on specimens.(Abe et 
al., 2010) This suggests defective mitochondrial function within the pulmonary arteries 
contributes to the pathophysiology of PAH.  
Fawn-hooded rats (FHR) are a unique strain of rodents that develop PAH spontaneously. 
There is decrease in size and fragmented appearances of mitochondria in PSMCs before the 
development of PAH with pulmonary vasculature remodelling. (Bonnet et al., 2006) In FHR 
there is evidence of mitochondrial dysfunction with deficient electron transport chain    
complex I and certain key mitochondrial enzymes. Metabolism as by oxidative 
phosphorylation is shifted to glycolysis with subsequent normoxic hypoxia-inducible factor 
(HIF) - 1α activation. This leads to reduced expression of oxygen-sensitive Kv channels with 
subsequent mitochondrial hyperpolization with associated vasoconstriction and proliferation 
of PSMCs. Mitochondrial network disruption occurs in the natural history of FHR at the 
ultrastructural level preceding haemodynamic changes.  Mitochondrial dysfunction occurs 
early in the pathogenesis of PAH either in FHR or human PAH. (Bonnet et al., 2006)   HIF-
1α over expression has accounted for lower numbers of mitochondria in human endothelial 
cells from PAH patients. (Fijalkowska et al., 2010) 
Impaired skeletal muscle energetics may contribute to physical disability and exercise 
intolerance in PAH patients. Monocrotaline rat modelling has shown with time, there is 
impaired mitochondrial respiration and biogenesis in skeletal muscle preceding any changes 
seen in the RV. (Enache et al., 2013) The exact reason why the change in peripheral muscle 
mitochondria occur before changes in mitochondrial activity in RV is unknown. 
Currently, whether mitochondrial OXPHOS dysfunction in skeletal muscle contributes to 
exercise intolerance in patients with PAH is uncertain. Early evidence suggests there maybe 
defects within skeletal muscle mitochondrial fusion but not within the oxidative enzyme 
pathways. (Batt et al., 2014) 
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1.5.5 31Phosphorous –magnetic resonance spectroscopy (31P-MRS) 
Skeletal muscle bioenergetics at rest and exercise can be measured non-invasively using 31P-
MRS. During exercise, the ATP used is resynthesized by glycolysis and oxidative 
metabolism by the mitochondria. (Argov et al., 2000) The concentration of ATP is held 
constant by a number of mechanisms. One of them is the creatine kinase (CK) reaction 
whereby phosphocreatine (PCr) is broken to down to donate the phosphoryl group to ADP to 
produced ATP. Therefore during exercise PCr levels fall. (Argov et al., 2000) 
ADP + PCr + H+                              ATP + Cr 
During recovery, oxidative phosphorylation by the mitochondria continues at an increased 
rate whilst glycolysis is stopped, in order regenerate the lost metabolites. Therefore PCr 
concentration increases due to predominantly mitochondrial work in healthy individuals. 
(Taylor et al., 1994) Phosphorous spectroscopy allows for the concentration of certain 
phosphate containing metabolites to be measured in various tissues during rest, exercise and 
recovery. The recovery kinetics of PCr generated can be measured by fitting best fit line to a 
single exponential curve to measure the time taken to regenerate half the concentration of PCr 
(t1/2). 
31P –MRS has been used in the study of mitochondrial myopathy, and has been shown 
in severe disease to have increased in PCr recovery times, correlating with muscle weakness. 
Furthermore, in mitochondrial myopathy 31P-MRS has shown increased recovery of the pH 
within the muscles due to rapid proton efflux seen in these patients. (Taylor et al., 1994) 
1.5.6 Summary 
The function of the skeletal muscle is crucial for movement and exercise. PAH seems to have 
a detrimental effect on muscle structure and function through a number of mechanisms. There 
have been no studies that have focused on the mitochondria within the skeletal muscle. 
Mitochondrial dysfunction is an understood part of the pathophysiology of PAH within the 
pulmonary vessel. Therefore, the question arises of whether there is any evidence of 
mitochondrial OXPHOS dysfunction in the skeletal muscle contributing impaired oxidative 
metabolism and leading to impaired exercise capacity. Exercise impairment and daily 
habitual activity are two ways of assessing the impact of the disease on the patient. Now, an 
overview of daily physical activity and the ways of measuring are discussed. 
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1.6 Habitual Physical Activity 
1.6.1 Background 
The lifestyle led by an individual person can have a profound effect on their health. The level 
of activity during a day can be broken into four types; sedentary, physical activity, exercise 
and sleep. The proportion of time spend in each individual section can affect a person’s 
metabolism and energy expenditure; therefore affect the onset and progression of chronic 
diseases. (Strath et al., 2013) 
Physical activity defined by Casperson et al is “any bodily movements produced by skeletal 
muscles that result in energy expenditure”. (Wittink et al., 2011) Exercise is a subcategory of 
physical activity and should not be regarded the same. Exercise involves structured, planned 
and often repetitive body movements based on exergy expenditure. (Caspersen et al., 1985) 
(Strath et al., 2013) Physical activity is any bodily movements, therefore includes sitting, 
socialising, exercise, household chores and transportation. (Caspersen, 1989, Strath et al., 
2013) Physical activity can be divided into sedentary, light, moderate and vigorous physical 
activity. Energy expenditure for activity is the metabolic equivalent of task (MET), with one 
MET equal to oxygen uptake of 3.5ml/kg/min, and is equivalent to the energy expenditure 
rate while sitting. (Hill et al., 2015). Light physical activity includes showering or ironing 
with 1.5-3 METs, with intensity between 20-40% of VO2max. (Strath et al., 2013) 
Maintaining physical activity is important to the overall health in a given population. Physical 
inactivity is associated with chronic diseases including coronary artery disease, type 2 
diabetes mellitus, hypertension, obesity, and depression. (Cloostermans et al., 2015, 
Bensimhon et al., 2006) A number of societies particularly in the field of coronary heart 
disease have published guidelines on assessing physical activity in their respective population 
groups. (Billinger et al., 2014, Strath et al., 2013)  They have promoted physically active 
lifestyle including levels of physical activity that should be achieved in a given week for 
health benefits. Despite the recommendations and known benefits, the majority of healthy 
patients fail to maintain regular physical activity levels. They suggest that physical activity 
should be assessed consistently in clinical and research settings. The benefits of monitoring 
physical activity levels is to reduce physical inactivity, improve risk factor modifications and 
for a greater knowledge into the health-related impact. (Tuso, 2015) 
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Sedentary behaviour can have a profound adverse effect on long-term health. (Wilmot et al., 
2012) The energy expenditure of sedentary behaviour is defined by low energy expenditure 
of less than 1.5 METs. (Sedentary Behaviour Research) Sleep is not considered sedentary 
behaviour but does include activities such as television watching, reading, driving, and use of 
computer. (Strath et al., 2013) Excessive sedentary time correlates with being overweight, 
low or even depressive symptoms, poorer quality of life, and elevated blood parameters of 
metabolic syndrome. (Tremblay et al., 2010, Bharakhada et al., 2012) The chance of early 
mortality is increased compared to the least sedentary group. (Wilmot et al., 2012) Even 
among patients considered physical active, those who spend a considerable amount of time in 
sedentary behaviour have increased all-cause mortality. (Katzmarzyk et al., 2009) Therefore, 
reducing the time spent in sedentary behaviour is crucial in improving long-term health in an 
individual.  
1.6.2 Measuring physical activity 
There are a number of ways of measuring energy expenditure and daily activity levels. These 
are discussed below, including subjective and objective methods. .  
1.6.2.1 Questionnaires 
There are a varied number of physical activity questionnaires that consists of either self-
reporting by keeping daily logs, answers to set questions or an interview like format. 
(Silsbury et al., 2015) Within the answers given in most questionnaires, the investigator can 
often accurately rank order the most active individuals to the least active. (Strath et al., 2013) 
However, it is recognised questionnaires are less able to identify activity in the sedentary-low 
range and can have poor correlation with objective assessments of physical activity. (Strath et 
al., 2004) 
1.6.2.2 Energy expenditure assessment 
Indirect Calorimetry - this involves the measurement of energy expenditure within the 
laboratory setting and is considered the reference standard. Essentially, the participant 
breathes either room air or mixture of gases with a known concentration and expired gases 
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are collected. This only measures energy expenditure not actual daily physical activity. 
(Strath et al., 2013) 
Doubly Labelled Water Method – measures total energy expenditure in living individual over 
1 to 3 week period. Two stable isotopes, oxygen -18 (18O) and deuterium (2H) are ingested 
and their respective differential elimination rates is measured representing carbon dioxide 
production over the period of time. (Strath et al., 2013) 
1.6.2.3 Accelerometers 
Accelerometers have the capability of capturing body movements in terms of duration, 
frequency and intensity. The device is attached to the body by a strap to the wrist, hips or 
ankles. They measure acceleration (body movements) in different planes and modern 
accelerometers are triaxial (measures movements in three planes). The data is stored and 
measured in gravity (g). This can be transformed into other units including the counts per unit 
time. The count observed is dependent on the individual accelerometer due to how 
acceleration data is transformed. (Strath et al., 2013) The measured units using predictive 
equations can be translated into energy expenditure expressed as kilocalories or METS. This 
allows certain threshold for particular activities and assessing how long an individual spends 
in a day or week doing activities of particular intensity.  
Accelerometers that generate count-based units have intrinsic advantageous of requiring 
lower computational memory, however, different accelerometers can generate different 
counts for the same acceleration signal. (Marschollek, 2013)  This makes comparison of 
studies that employ different accelerometers difficult to interpret. The measurement of raw 
acceleration data has meant that acceleration data are no longer stored as propriety counts and 
can be transformed into values that are comparable between studies. (Bakrania et al., 2016, 
John et al., 2013)  
Acceleration signal consists of three components including movement, gravitational and 
noise. (van Hees et al., 2013) The noise and gravitational components have to be separated 
out or corrected from the acceleration signal. This is complicated by rotational movements 
making the separation of gravity and movement more difficult. There are a number of 
different mathematical ways this can be achieved.  One of them is the Euclidean Norm Minus 
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One (ENMO). The Euclidean Norm is the vector magnitude of the orthogonal acceleration. 
From this value one gravity unit is subtracted. (Bakrania et al., 2016) ENMO values are 
calculated for each 5 seconds epoch. From these, the proportion of time spent by an 
individual undertaking various physical activities can be determined.  
The GenieActiv® wrist-worn accelerometer measures raw acceleration and has been 
validated in a number of studies. (Bakrania et al., 2016, Pavey et al., 2016, Powell et al., 
2016, Schaefer et al., 2014, Zhou et al., 2015) Acceleration values for moderate to vigorous 
physical activity has been determined using ENMO as approximately more than 100 mg. 
(Hildebrand et al., 2014) Acceleration between 0-40 represents inactive behaviour, whilst 
those between 40-80 and 80-120 represents phases between inactive to active behaviour. 
(Charman et al., 2016) The GenieActiv® monitor is easy to use in patients studies without 
having to be removed, and accurately reflects daily habitual physical activity. 
1.6.3 Physical activity, metabolic syndrome and PH 
Metabolic syndrome can result systemic vascular dysfunction through clinical and 
biochemical abnormalities. (Grundy et al., 2004) Physical inactivity has deemed as factor 
associated with increased risk of developing illnesses such as type 2 diabetes and 
cardiovascular disease.(Hill et al., 2015) There is an increasing recognition that metabolic 
syndrome is associated with pulmonary hypertension. (Paulin and Michelakis, 2014) Glucose 
intolerance is increasingly seen at diagnosis in PAH. (Pugh et al., 2011) Furthermore, 
pulmonary hypertension develops in peroxisome proliferator activated-receptor-γ (PPARγ) 
and adiponectin – deficient mice, suggests there is potential role of insulin-resistance in the 
development of PAH. (Wilkins, 2012) As the age of diagnosis of PAH increases and existing 
patients are living longer with treatment are likely to develop co-morbidities, this is an area 
that requires further investigation.  (Ling et al., 2012) 
1.6.4 Physical activity in PH 
Physical activity research in PAH has been limited so far. Mainguy et al, demonstrated 
reduced daily physical activity levels compared to controls with reduced number of  daily 
steps, decreased  daily energy expenditure and decreased time spent performing physical 
activities needing greater than three METs. The number of daily steps correlates with 6MWD 
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and WHO functional class. (Mainguy et al., 2011)  Pugh et al showed that PAH patients 
spend an increased proportion of time undertaking sedentary activities (Pugh et al., 2012) 
Whilst proven targeted treatment leads to improved submaximal and maximal exercise 
capacity, their respective effects of habitual daily activity is unknown.  
 
1.7 Fatigue 
Fatigue is a commonly applied term in both healthy and diseased individuals. Fatigue is a 
complaint upon physical exertion such as after running or a manifestation of an underlying 
disease. (Finsterer and Mahjoub, 2014). In healthy people fatigue improves with rest, whilst 
diseased individuals report fatigue at rest and exertion, limiting their daily activities. (Davis 
and Walsh, 2010). There are both central and peripheral mechanisms that may underlie 
patient reported fatigue. (Finsterer and Mahjoub, 2014) These include peripheral muscle 
function including the role of skeletal bioenergetics and the coupling that leads to muscle 
contraction. (Davis and Walsh, 2010) Understanding the factors leading to fatigue in 
individual diseases may help to develop interventions as part of multi-focused treatment 
plans.   
Fatigue in PAH is a common complaint among patients that persists despite targeted therapy. 
(Matura et al., 2012)  The mechanisms underlying fatigue in PAH remains uncharacterised, 
but exercise intervention seems to improve patient reported fatigue scores. (Weinstein et al., 
2013a) Furthermore, as discussed previously physical activity levels is reduced in PAH and 
the fatigue maybe contributing to this particular aspect of daily living. (Pugh et al., 2012, 
Weinstein et al., 2013b) There needs to be a greater understanding of the impact, mechanisms 
and potential viable treatment of fatigue for patients with PAH. 
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1.8 Summary of literature review 
Pulmonary Arterial hypertension has been introduced as a multi-systemic disease that has 
pathophysiological effects beyond the pulmonary vessels. Skeletal muscle dysfunction in 
PAH has gained increased prominence as a potential independent factor contributing to 
functional and exercise limitations in recent publications. Mitochondrial dysfunction in the 
pulmonary vessel plays a significant role in the pathology of PAH leading to impaired 
apoptosis and proliferation of cells. There is some early evidence of potential mitochondrial 
dysfunction in the skeletal muscle. The physiology that leads to exercise limitation in PAH 
patients was discussed. The majority of research has focused on central resting and exercise 
haemodynamic particularly on supine exercise. Peripheral factors that affect the oxygen 
pathway further downstream from the cardiac pump function have gained little attention.  
Patients report fatigue as a common symptom of exercise and activity limitation. Compared 
to healthy controls, PAH patients have reduced activity levels and spend a greater proportion 
of time undertaking sedentary tasks of living. Therefore, there needs to be a further 
understanding of skeletal muscle function, factors affecting exercise capacity, and how 
current treatments influence daily activity levels in PAH patients.  
1.9 Aims of Thesis 
Therefore, with consideration of the information above, the aims of the thesis were to answer 
following questions: 
1. Is there any evidence that impaired skeletal muscle mitochondrial function in 
idiopathic pulmonary arterial hypertension contributes to exercise intolerance? 
2. What are the relative roles of central and peripheral limitations to exercise in 
pulmonary hypertension? 
3. What is the effect of PH-targeted treatment on habitual daily activity levels in 
patients? 
4. What is the impact of patient reported fatigue on daily activity levels and quality 
of life? 
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Chapter 2 Material and Methods 
2.1 Recruitment Strategy and Informed Consent Process 
All participants with pulmonary hypertension were actively recruited from the National 
Pulmonary Hypertension Service (Newcastle). Potential patients were identified prior to 
outpatient clinics and then approached during their regular clinic visit. They were screened 
according to the inclusion and exclusion criteria. The study including any potential risks were 
explained and participant information sheet was provided. They were phoned after a 
minimum of 48 hours to determine if they wished to participate and any further questions 
answered. Studies underwent ethical approval by relevant organisations and the patient 
consent forms are given in the appendices C and D.  
2.2 Baseline Clinical Characteristics 
All the participants in the various studies had established diagnosis of pulmonary 
hypertension made at a designated specialist centre (Newcastle). Background clinical 
information data were retrieved including age, gender, height, weight, WHO-FC, aetiology of 
pulmonary hypertension, recent cardiopulmonary haemodynamics by right heart 
catheterisation, current targeted therapies, 6MWD and NT-proBNP. These data are presented 
in the respective chapters.  
2.3 31Phosphorous –Magnetic Resonance Spectroscopy (31P-MRS) 
Chapter 3 involves a pilot study of six participants with idiopathic pulmonary arterial 
hypertension (IPAH) who underwent 31P-MRS. The use of 31P-MRS allows us to study 
skeletal muscle bioenergetics by assessing the changes in the concentration of phosphate 
metabolites during rest, exercise and recovery. The spectroscopy data can be used to 
determine the relevant concentration of a variety of metabolites and calculate the intracellular 
pH handling.  
2.3.1 Basic principles of 31P-MRS 
31P-MRS is method of measuring the resonance frequency of phosphate metabolites in a 
number of organs during stress using non-invasively. (Kemp et al., 2007)  The mitochondria 
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in any cell has a vital role in the production of phosphate metabolites particularly adenosine 
triphosphate (ATP) to be used by the cell as a source of energy. 31P-MRS is able to detect the 
signal of unbound phosphate metabolites with a concentration of at least 1mM. As the 
method is non-invasive, it can be used to monitor changes in the concentration of phosphate 
metabolites during rest, exercise and recovery. Therefore, the monitoring of oxidative and 
glycolytic metabolism is possible. (Kemp et al., 2007) Basic principles of skeletal muscle 
bioenergetics are shown in Figure 7 (below) (Prompers et al., 2014) 
Individual cells have three sources of ATP generation: 
 a) Oxidative phosphorylation by mitochondria of adenosine diphosphate (ADP) and 
phosphate metabolite (Pi) to produce ATP.  
 b) Hydrolysis of phosphocreatine (PCr) to produce ATP, requiring hydrogen ion. 
 c) Glycogenolysis leading to lactate and ATP 
To assess mitochondrial function, we can observe a number of parameters including changes 
in PCr recovery time (PCr t1/2), ADP recovery time (ADP t1/2), and pH during exercise and 
relative concentration of the metabolites, to assess any suggestion of mitochondrial 
dysfunction in skeletal muscle.  
Skeletal muscle oxidative capacity which is an assessment of mitochondrial function can be 
monitored in terms of recovery of PCr after exercise by the use of 31P-MRS. The re-synthesis 
of PCr in recovery is a result of mitochondrial ATP production as the CK reaction is stable or 
rather in equilibrium (Lanza et al., 2011). ADP recovery is calculated indirectly as most ADP 
is bound therefore cannot be measured directly (Arnold et al., 1984). Muscle pH during 
exercise is calculated using the gap between the spectra between PCr and Pi as shown in 
Figure 7. (Prompers et al., 2014) 
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Figure 7: Basic principles of energy production in skeletal muscle.  
ATP hydrolysis leads to ADP and Pi. ATP production is driven by demand (e.g. muscle 
contraction). During steady state, ATP demand (green) is matched by production (blue). 
During supply-demand mismatch, the CK reaction (purple) helps to supply the extra ATP. 
During short duration exercise the mitochondrial oxidative phosphorylation system generates 
the required ATP to meet demands during and in recovery. The shaded grey block represents 
what is visible to the 31P-MRS to be detected; PCr, Pi and ATP, with ADP and pH calculated 
indirectly. (Figure from Pompers et al, 2014) 
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Figure 8: Spectral peaks of 31P-MRS. 
MR signal can detect peaks of PCr, Pi and three peaks of ATP (γ, α and β in that order). The 
gap between PCr and Pi can be used to calculate the pH. (Figure from Dr K Hollingsworth) 
 
2.3.2 31P-MRS protocol used and analysis of data 
Six participants underwent 31P-MRS scan with a 3T Intera Achieva Scanner (Philips, MA, 
USA). A 14cm diameter phosphorus coil was used for the transmission and reception of 
signal as well as for the coil used for anatomical imaging. The 31P-MRS protocol was 
designed by the Newcastle MR centre and processing of data was automated by systems 
developed by Drs Jehill Parikh and Kieren Hollingsworth. The methodology has been 
described in previous literature and is described below (Hollingsworth et al., 2008, Payne et 
al., 2014) . 
Each subject performed two periods of exercises at 25% and 35% maximum voluntary 
contraction (MVC). The MVC was determined before the start of spectroscopy. There was 
three minutes of rest, three minutes of plantar flexion at 0.5Hz (using a metronome) and 5 
minutes of rest to measure recovery in equilibrium. (Hollingsworth et al., 2008) In the first 
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instance a 25% MVC at a fixed load was used to measure oxidative metabolism in recovery 
aiming to change the pH levels as little as possible. The second period, after ten minutes of 
rest, 35% MVC at a fixed load was used generating greater anaerobic metabolism and 
resulting in measurement of pH handling. Phosphorous spectra was collected at 10s intervals 
throughout the exercise to identify signals to the gastrocnemious and soleus muscles. 
(Prompers et al., 2014) (Figure 8) The exercise was performed using MR compatible plantar 
flexion exercise apparatus, with the use of restraining straps to prevent the aid of other 
muscle groups (e.g. quadriceps). (Hollingsworth et al., 2008) 
The jMRUI processing software was used to measure values for PCr, inorganic phosphate 
and pH. There was an assumption that a value of 8.2mM ATP at rest and as well as correction 
of the values of spectroscopy at relative saturation at rest. ADP concentrations were 
calculated using PCr and pH measurements, with the use of the creatine kinase equation, at 
each time point. Standard methods as described in published literature were employed to 
assess oxidative metabolism and pH handling (Kemp and Radda, 1994). Exponential fits to 
the recovery data were made to estimate the half-times for recovery to equilibrium of ADP 
and PCr. All spectroscopy analysis for the six participants presented in Chapter 3 was 
performed by Dr Jehill Parikh.  
 
2.4 Skeletal Muscle Biopsy and Laboratory Analysis 
Skeletal muscle biopsies were obtained to study the in vitro mitochondrial oxidative 
phosphorylation function. The process of obtaining, storage and the laboratory techniques 
used at our centre are described below. The results of the study are reported in Chapter 4. The 
biopsy was undertaken at the Clinical Research Facility, Royal Victoria Infirmary, Newcastle 
upon Tyne. 
2.4.1 Obtaining and storage of the muscle biopsy 
Biopsy of the vastus lateralis  muscle was performed under local anaesthesia using a modified 
ethmoid needle (conchotome forcep), as previously described. (Taivassalo et al., 2006)  In 
brief, using aseptic technique, 2% lignocaine of 10ml was used to anaesthetize the area, 
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without infiltrating the muscle. A small incision was made up to the fascia, and using the 
conchotome needle, 2 to 3 pieces of skeletal muscle tissue was obtained. Manual pressure 
was applied for minimum of 10 minutes, with incision closed with steri-strips and a 
waterproof dressing. The quadricep muscle was wrapped using a crepe bandage for 1 hour 
after which it was removed and the dressing inspected.  
Extracted muscle tissue was snap frozen in liquid nitrogen and stored at -80oC. For laboratory 
analysis, sections of 10µM thickness muscle tissue was obtained using a cryostat at -20oC and 
fixed on positively charged slides (Superfrost®), air dried for 1 hour at room temperature and 
stored at -80oC.  
2.4.2 Histochemical staining 
Slides containing 10µm cut sections of transversely orientated muscle sections, were allowed 
to thaw for 1 hour at room temperature. Individual activities of mitochondrial enzymes 
consisting part of the oxidative phosphorylation system was assessed. Thus, histochemical 
staining as previously described for cytochrome C oxidase (COX, complex IV), succinate 
dehydrogenase (SDH, complex II), and then sequential assay of COX/SDH activity (Old and 
Johnson, 1989) were undertaken with aid of Mr G Falkous.  
Haematoxylin and Eosin Staining: Muscle sections placed in Harris’ haematoxylin for 3 
minutes, washed in tap water, differentiate in 0.2% acid alcohol, place in 1% eosin for 15-20 
seconds, wash in distilled water, dehydrate in ascending alcohol series and mount in synthetic 
resin (DPX). 
COX/SDH staining: Sections were reacted for 45mins at 37oC with COX reaction media 
(4mM diaminobenzidine tetrahydrochloride, 100µM, cytochrome c and 20µg/ml catalase in 
0.2M phosphate buffer, pH 7.0) and 40 min at 37oC with SDH media (1.5mM nitroblue 
tetrazolium, 1mM sodium azide, 200µM phenazine methosulphate, 130mM sodium 
succinate, in 0.2 M phosphate buffer, pH 7.0) Sequential COX/SDH staining highlights 
individual myofibres that are COX-deficient which appear as blue staining myofibres under 
light microscopy. (Old and Johnson, 1989) 
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Gomori trichrome: GT staining was undertaken to assess for the presence of ragged-red 
muscle fibres due to subsarcolemmal accumulations of mitochondria. Muscle sections are 
placed in Harris’ haematoxylin for 5 minutes, rise in distilled water, stain in Gomori 
trichrome mixture for 10 minutes, rinse in tap water, dehydrate in ascending alcohol series 
and mount in synthetic resin. (Rifai et al., 1995) 
2.4.3 Quadruple immunofluorescence 
Immunofluorescent staining was undertaken based on methodology developed by the 
Wellcome Trust Mitochondrial laboratory, Newcastle and described previously (Rocha et al., 
2015). This is a highly sensitive and specific technique to assess defects in the mitochondrial 
OXPHOS pathway in the skeletal muscle, beyond those achieved by visual assessment of 
muscle fibres using histochemical techniques. Quadruple immunofluorescence allows for 
appropriate adjustment for mitochondrial mass and analysis of individual muscle myofibre.  
Procedure: Snap frozen muscle sections on Superfrost® slides were dried, fixed in 4% 
paraformaldehyde (Sigma) for 3 minutes and permeabilised in methanol (Fisher) gradient  
(10mins 70% methanol, 10mins 95% methanol, 20mins 100% methanol, 10mins 95% 
methanol and 10mins 70% methanol). 10% normal goat serum was used to block non-protein 
interactions.  Incubation overnight in humidified chamber at 4oC with primary antibodies 
against complex I (subunit NDUFB8), complex IV (subunit COX-I), mitochondrial mass 
antibody against porin and myofibre boundries were labelled with anti-laminin antibody.  
After washes in TBST, sections were incubated with secondary antibodies for 2 hours at 4oC.  
Sections were then incubated for 2 hours at 4oC with streptavidin conjugated with Alexa 647. 
After washing, the sections were mounted in Prolong Gold (Sigma). No primary control 
(NPC) sections were incubated with anti-laminin antibody only. (Rocha et al., 2015)  
Image acquisition: Fluorescent images were obtained with Zeiss Axio Imager M1 and Zen 
2011 software, using a monochrome digital camera (AxioCam MRm) at 20× magnification. 
Filter cubes at 405nm, 488nm, 546nm and 647nm wavelengths for laminin, COX-I, porin and 
NDUFB8 respectively were used. (Rocha et al., 2015) Varying number of muscle fibres were 
imaged according to the size of the muscle sections.  
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Data analysis: First, the images obtained were analysed using IMARIS software (Bitplane). 
Individual muscle myofibres were separated manually. Surfaces were created within the 
myofibre. Optical density readings were measured (COX-I, NDUFB8 and Porin), within each 
myofibre. No primary controls were used to obtain mean optical density for non-specific 
fluorescence.  
Further statistical analysis was undertaken using the obtained optical density measurement 
for each myofibre. This was performed using r studio program (version 3.1.3) by Dr John 
Grady. Values for OXPHOS complex values were corrected for mitochondrial mass and for 
background signal for each muscle myofibre. Z-values were obtained from the control 
population (healthy and disease controls) for each subunit of complex I and IV according to 
the porin level. Fibres were classified for complex I and IV according to standard deviation 
limits, with normal being Z > -3SD, intermediate with Z between -3SD to -6SD and deficient 
if Z-score <-6SD.  
 
2.5 Cardiopulmonary Exercise Testing 
Incremental symptom-limited CPEX testing was performed using electronically-braked cycle 
ergometer (Ergoline®). We used the standard exercise protocol established at our institution 
for all patients with pulmonary hypertension, involving a step protocol increasing the work 
rate by 10 Watts per minute. All participants were required to pedal at a frequency around 60 
revolutions per minute. Borg dyspnoea score was assessed at rest and at peak exercise. 
Continuous 12-lead electrocardiograph and pulse oximetry monitoring was employed 
throughout the exercise and recovery period. Gas exchange variables were measured breath 
by breath using gas analyser (Medgraphics Cardio 2 Ultima). Anaerobic threshold was 
determined by the V-slope method and lowest ventilator equivalent of oxygen (Beaver et al., 
1985).  Systemic blood pressure was recorded at rest and peak exercise. Participants stopped 
exercising due to intolerable peripheral leg fatigue and/or severe dyspnoea. There were no 
adverse events observed during any CPEX testing of participants. All tests were performed in 
the presence of respiratory physiologist and a physician. 
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The healthy control data was used to compare the central and peripheral haemodynamic 
response to symptom-limited maximum exercise data of patients with pulmonary 
hypertension. This was undertaken using a variable ramp protocol of increasing work rate of 
5 – 20 Watts/min at 60 revolutions per minute. CPEX testing was performed by staff at the 
MoveLab, Clinical Research Facility, Royal Victoria Infirmary, Newcastle and grateful for 
allowing for the use of the data. (Dr Djordje Jakovljevic)  
2.6 Non-Invasive Central Haemodynamic Monitoring 
During CPEX testing, central haemodynamics was monitored using non-invasive method, 
NICOM ® (Cheetah Ltd, Israel). NICOM® allows for continuous monitoring of stroke 
volume, stroke volume index, heart rate, cardiac output and cardiac index throughout the 
exercise period. (Jakovljevic et al., 2012a) 
This methodology is dependent on bioreactance technology which is when an alternating 
current (AC) is passed through the thorax leading to time delay (phase shift) to occur. 
(Jakovljevic et al., 2012a) The patient is attached with four transmitting sensors and 
additional four receiving sensors. The detection of phase shift in AC current is correlated 
with stroke volume. The heart rate is detected by the same sensors, and cardiac output can 
then be calculated. (Figure 9).  
The NICOM® has shown good test-retest reliability at rest and throughout graded maximum 
exercise (Jones et al., 2015). Furthermore, it has been shown  in patients with pulmonary 
hypertension to correlate well with established invasive methods of assessing cardiac output 
particularly thermodilution during resting right heart catheterisation (Rich et al., 2013).  
During the CPEX testing, after placing the patient on the upright cycle ergometer, the four 
double electrodes were placed on the back and connected to the NICOM® device using four 
wires. (Figure 10) The NICOM® continuously monitored cardiac output every 30 seconds.  
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Figure 9: Diagram of the basic principles behind NICOM®. 
 
The AC is based on the sine wave. Therefore, the green sine wave starts 0.25seconds before 
the black sine wave. The black sine wave is phase shifted by 90o or quarter of cycle from the 
green sine wave. This angle can be used to calculate the stroke volume. (Reproduced from 
Cheetah Medical®) 
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Figure 10: Demonstrates the four electrodes (transmitter/sensor) in their respective 
position.  
 
The monitor induces an electrical current (labelled with i) with a frequency of 75KHz. The 
returning voltage is detected on both sides (labelled as V). The monitor measures the time 
delay between i and v, thus detecting the phase shifts. (Reproduced from Cheetah Medical®) 
 
2.7 Habitual Physical Activity Monitoring 
In chapter 6, we studied the habitual physical activity (HPA) of patients with pulmonary 
hypertension in a pilot study. We studied the effect of starting, adding or changing pulmonary 
hypertension-targeted therapies on physical activity at 3 and 6 months from baseline. 
2.7.1 Accelerometer  
Accelerometers (GENEActiv, Activinsights Ltd, UK) were used to capture habitual physical 
activity over a 7-day period under free-living conditions. The accelerometers were wrist-worn 
and each participant activity was recorded at baseline, 3 and 6 months. Instructions were 
provided to each participant on how to wear the accelerometer. The activity monitor was pre-
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programmed to start recording at a specified time point. The activity monitor is a tri-axial 
accelerometer with a sample frequency configured at 50Hz. The sensor is parallel to the 
longitudinal axis of the radius and the z-sensor is perpendicular to the skin surface when 
attached to the skin surface. The dynamic range of the sensors is ±8g and store data at 
resolution of 12bit. There is temperature and light sensor on the accelerometer. Furthermore, 
it is waterproof to 10 metres and weighs 16grams without the straps. (Charman et al., 2016) 
2.7.2 Data analysis 
The process has been described by MoveLab, Newcastle University in previous publications 
and is described below as such. The data was processed in R (www.cran.r-project.org) by Dr 
Sarah Charman. The first and last hour of data were disregarded due to monitor disruption of 
distribution and collection. Only days with a minimum of 16 hours collected were kept for 
analysis. (Charman et al., 2016) 
The average acceleration on the wrist per 5 second epoch was determined using ENMO. The 
ENMO is in mg (1mg = 0.001g = 0.001 × 9.8 m/s2 = 0.001 × gravitational acceleration). (van 
Hees et al., 2013) Accelerometer non-wear was detected as described before. (van Hees et al., 
2013) If the participants took off the monitor deemed non-wear time, the data was replaced 
from same time points from other days of measurement. The data from the time series was 
used to calculate the total time in particular acceleration categories per day. (Charman et al., 
2016) Category 0 -50 mg is inactive behaviour; category 50-100mg is a marginal zone 
between active and inactive behaviour (e.g. such as sitting but moving your arms or slow 
walking but not moving your arms); categories greater than 100 – 150 mg is moderate and 
vigorous physical activity (MVPA). Moderate-to-vigorous physical activity was determined 
by using the ≥ 100 mg cut-off. (Hildebrand et al., 2014) Furthermore, the least active 5 hour 
period (L5) and the most active 5 hour period (M5) along with the difference between the two 
periods (ΔM5L5) were calculated in mean acceleration (mg). (Innerd et al., 2015, Charman et 
al., 2016) 
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2.8 Quality of Life and Fatigue Severity Questionnaires 
We assessed the quality of life and fatigue severity of patients with pulmonary hypertension 
in the studies involving all the chapters. We monitored response and change in quality of life 
and fatigue severity with targeted therapy whilst monitoring habitual physical activity in 
chapter 6.  
2.8.1 EmPHasis -10 questionnaire 
This questionnaire has been validated for PH patients in assessing health-related quality of 
life (HRQL). It consists of 10 questions, presented as a six-point differential scale (0-5), 
giving a total score out of 50, with a higher range reflecting worse quality of life. The 
questionnaire has shown good correlation with WHO functional class, dyspnoea and 
psychological distress (Yorke et al., 2014).  
2.8.2 Fatigue severity scale (FSS) 
The questionnaire measures patient’s view of how fatigue affects their physical and social 
behaviour. There are nine situations where patients’ are asked to make a response of how 
fatigue affects these situations. (Rosa et al., 2014) The scoring is based on Likert scale where 
1 for strong agreement to 7 for strong disagreement. The scoring is completed by calculating 
a mean response and is a validated tool. (Valko et al., 2008) Furthermore, it has been used to 
assess response to exercise training in PH patients. (Weinstein et al., 2013b) 
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Chapter 3 In Vivo Study of Skeletal Muscle Mitochondrial Function in 
Idiopathic Pulmonary Arterial Hypertension 
3.1 Introduction 
Idiopathic pulmonary arterial hypertension (IPAH) results in obstruction to blood flow in the 
pulmonary arteries leading to right ventricle failure. (McLaughlin and McGoon, 2006) 
Increasingly, IPAH is being recognised as a multi-systemic disease process with the role of 
insulin resistance, skeletal muscle dysfunction, bone-marrow derived mononuclear cells and 
iron-deficiency contributing to exercise intolerance experienced by IPAH patients. (Paulin 
and Michelakis, 2014) Currently available therapies include phosphodiesterase V inhibitors, 
endothelin receptor antagonists and prostacyclin analogues which act on targets within the 
pulmonary artery. (Humbert et al., 2014) Aside from primary pathophysiology, there is 
increased focus in understanding causes of exercise intolerance and fatigue beyond the 
pulmonary vasculature. In the last decade, exercise rehabilitation has shown to be safe and 
beneficial in patients with IPAH by increasing their exercise capacity and quality of life. 
(Grunig et al., 2012a)  
Skeletal muscle dysfunction contributes to exercise intolerance and reduced muscle strength 
in IPAH patients. (Mainguy et al., 2010, Bonnet et al., 2006, Archer et al., 2008) 
Mitochondrial dysfunction is recognised to be contributing to the pathophysiology of IPAH 
in the pulmonary arteries. (Ryan and Archer, 2015) More recently, there is evidence of a 
potential role of mitochondrial oxidative phosphorylation dysfunction in the skeletal muscle 
of IPAH patients contributing to exercise intolerance. (Malenfant et al., 2015) However, the 
proteomic analysis methods used have their limitations including a “shot-gun” approach to 
analysis, lack specificity to individual expression of specific proteins and failure to adjust for 
mitochondrial mass. Furthermore, their ex vivo analysis does not reveal in vivo performance.  
31Phosphorous –magnetic resonance spectroscopy (31P-MRS) is a non-invasive method of 
measuring the phosphate metabolites in vivo. 31P-MRS is able to detect the signal of unbound 
phosphate metabolites with a concentration of at least 1mM. (Kemp et al., 2007) As the 
method is non-invasive, it can be used to monitor changes in the concentration of phosphate 
metabolites during rest, exercise and recovery, making it possible to monitor oxidative and 
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glycolytic metabolism. Further principles and mechanisms relating to 31P-MRS are discussed 
in chapter 2.   
The primary aim of this pilot study was to assess in vivo mitochondrial function in the 
skeletal muscles of patients with IPAH compared to healthy controls without mitochondrial 
disease. The secondary aims were: 1) To explore skeletal muscle intracellular pH handling 
during and after exercise in IPAH 2) To determine any association between skeletal muscle 
bioenergetics, and self-reported quality of life and fatigue severity.   
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3.2 Methods  
3.2.1 Study design 
Six IPAH patients underwent 31P-MRS scan. All six participants were clinically stable, in 
WHO functional class 2 or 3 and established on PAH-targeted therapies. They had no 
contraindications to undergoing magnetic resonance scans. They did not have any other 
cardiovascular, pulmonary, neurological and musculoskeletal co-morbidity. All six 
participants completed quality of life questionnaires (EmPHasis-10) and fatigue severity 
(FSS).  
The study was approved by the Newcastle and North Tyneside 2 ethics committee, 
13/NE/0353. All participants gave informed written consent for the study. The scans were 
performed by trained radiographers at the Newcastle Magnetic Resonance Centre. The 
spectral analyses were performed by physicists at the MR centre. (Dr Jehill Parikh and Dr 
Kieren Hollingsworth). The main principles of the 31P-MRS scan and methodology are 
described in Chapter 2. The primary outcome variable was phosphocreatine recovery half-
time (PCR t1/2) as a marker in vivo mitochondrial function. The secondary outcome variable 
included adenosine diphosphate recovery half-time (ADP t1/2), intracellular pH, patient-
reported quality of life and fatigue severity.  
3.2.2 Statistical analysis 
Data was assessed to be non-parametric due to the small number involved and by Shapiro –
Wilk test. Comparison to healthy control data were analysed using Kruskal-Wallis test. P-
value less than 0.05 were considered significant. All data analysis was performed using SPSS 
version 21(Chicago, IL). All continuous data are given as mean ± standard deviation. This 
was a pilot study, to stimulate a main trial into skeletal muscle bioenergetics in IPAH. Based 
on a power calculation 90% chance of detecting a difference, with 0.05 alpha and 0.1 beta 
value, nine patients would be needed in the main trial.   
50 
 
3.3 Results 
3.3.1 Baseline characteristics 
Individual patient characteristics of all six patients are shown in Table 1. No participants 
were on intravenous prostacyclin infusion as the pump was ferromagnetic and therefore 
contraindication to MR scanning. 
3.3.2 Skeletal muscle mitochondrial function  
31P-MRS data are presented in Table 2. The main outcome measure was the recovery kinetics 
of phosphocreatine (PCr) as an in vivo marker of mitochondrial oxidative phosphorylation 
function. There was observed delayed recovery in four participants with the remaining two 
participants having normal PCr recovery kinetics compared to healthy controls (40.0 ± 8.8 vs 
27.2 ± 7.1 seconds, p = 0.013). There was greater inter-individual variation in PCr recovery 
kinetics among IPAH patients than with healthy normal controls (range 30.67-56.03 vs 
control range 18.42-39.04). Phosphocreatine, inorganic phosphate resting content, and ADP 
recovery half-time were not different to controls (Table 2, P > 0.05). There was no close 
relationship between the kinetics of ADP and PCr recovery times (Figure 11, below r2 
=0.027, p = ns) compared to literature healthy controls   (r2=0.78, p < 0.005).  
3.3.3 Intracellular pH handling in skeletal muscle 
IPAH patients had on average significantly lower minimum pH values during exercise than 
healthy controls (7.00 ± 0.02 vs 6.85 ± 0.10, p = 0.001). The start and end-pH were not 
different to controls. (Table 2, P > 0.05).  IPAH patients demonstrated evidence of an 
increase in pH recovery times compared to controls (197 seconds, range 130-240 vs 58 
seconds, range 0-160). 
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Table 1: Baseline Characteristics  
Patient Age/Gender BMI 
(kg/m2) 
WHO FC mPAP 
(mmHg) 
CO 
(L/min) 
CI 
(L/min/m2) 
PVR 
(Wood units) 
Treatment 6MWD (m) 
1 29F 40 3 42 5.9 2.5 6.4 PDE5i 420 
2 52M 32 2 20 6.8 3.0 2.5 PDE5i 402 
3 48F 28 2 31 7.5 4.1 2.3 PDE5i and ERA 374 
4 69F 26 2 46 4.0 2.5 10.1 ERA 376 
5 40M 28 2 37 4.8 2.5 6.8 PDE5i 520 
6 43F 24 2 33 4.9 2.8 5.1 PDE5i and ERA 455 
Abbreviations: BMI – Body Mass Index, WHO FC – World Health Organization Functional Class, mPAP – mean pulmonary artery pressure, 
CO – cardiac output, CI – cardiac index, PVR – pulmonary vascular resistance, 6MWD – six minute walk distance. PDE5i – Phosphodiesterase -
5-inhibitor (Sildenafil or Tadalafil), ERA – endothelin receptor antagonist (Bosentan or Ambrisentan) 
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Table 2: 31P-MRS readings obtained from PAH and healthy control participants 
31P-MRS readings Healthy Controls 
(n=8) 
PAH 
 (n=6) 
P-value 
PCr t1/2 27.2 ± 7.1 40.0 ± 8.8 0.013 
ADP t1/2 20.9 ± 5.1 25.5 ± 7.1 0.228 
Rest pH 7.04 ± 0.02 7.03 ± 0.02 0.573 
End Exercise pH 7.02 ± 0.02 7.02 ± 0.04 0.573 
Minimum pH 7.00 ± 0.02 6.85 ± 0.10 0.001 
Rest PCr (mM) 33.6 ± 2.7 32.1 ± 1.8 0.345 
Resting Pi (mM) 3.13 ± 0.81 3.05 ± 0.36 0.950 
PCr t1/2 – phosphocreatine recovery half-time, ADP t1/2 – adenosine diphosphate recovery 
half-time, Pi – inorganic phosphates, mM - millimoles 
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Figure 11: Scatter plot of ADP and PCr recovery half times of individual IPAH patients.  
There is no significant correlation between the two values. 
 
3.3.4 Phosphocreatine recovery kinetics, quality of life and fatigue severity 
Given the small number of participants, formal statistical analysis was not undertaken to look 
for correlation between indices derived from 31P-MRS, quality of life and fatigue severity. 
Table 3 shows individual patients PCr recovery times, scores given for emPHasis-10 and 
fatigue severity scale. Overall, there is no clear pattern emerging to suggest correlation of 
what was measured in terms of skeletal muscle bioenergetics and patient-reported symptoms.  
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Table 3: Individual patient phosphocreatine recovery half time, quality of life and 
fatigue severity score. 
Patient PCr t1/2 (s) emPHasis-10 FSS 
1 56.0 35 3.9 
2 30.7 6 2.9 
3 34.6 29 4.9 
4 41.7 7 1.0 
5 39.7 29 6.0 
6 37.2 25 5.3 
Abbreviations: PCR t1/2 – phosphocreatine recovery half time in seconds, FSS – fatigue 
severity scale. Any value greater than 4 on FSS is deemed the patient suffers from severe 
fatigue.  
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3.4 Discussion 
This is the first pilot study to have used 31P-MRS to assess skeletal muscle bioenergetics in 
mitochondrial function in patients with idiopathic pulmonary arterial hypertension. The 
current pilot study has shown 1) IPAH patients have abnormal PCr recovery half-time and 
achieve lower minimum pH during exercise 2) The pattern of skeletal muscle bioenergetics 
observed is not consistent with an underlying mitochondrial dysfunction 3) There is no clear 
association between recovery kinetics of phosphocreatine and fatigue severity or quality of 
life scores.  
These data demonstrate that IPAH patients have significantly prolonged PCr recovery half-
time compared to control population without IPAH. In the recovery period after exercise, the 
regeneration of PCr is determined mainly by the oxidative capacity of the mitochondrial 
OXPHOS function in ATP resynthesis. (Thompson et al., 1985, Quistorff et al., 1993) 
Therefore, PCr t1/2 has been used as a surrogate in vivo marker of skeletal muscle 
mitochondrial function. Certainly in established mitochondrial myopathy, PCR t1/2 is 
increased in absolute terms due to delayed oxidative ATP synthesis and in relation to end 
exercise ADP concentration. (Taylor et al., 1994) Furthermore, PCr recovery half-times have 
a close correlation with in vitro mitochondrial function measured by respirometry. (Lanza et 
al., 2011) The extended PCr recovery is indicative of mitochondrial impairment, although 
given the pathophysiology of IPAH it is important to understand the physiological context of 
this. Using PCr t1/2 has its inherent limitation as mitochondrial function can be affected 
beyond defects in the OXPHOS system. PCr recovery is prolonged in patients with peripheral 
vascular disease or artificially induced limb ischaemia, where blood flow is reduced on 
exercise. (Hands et al., 1990) In COPD patients with reduced resting partial pressure of 
oxygen at rest, PCr t1/2 is increased but improves with oxygen supplementation during 
exercise. (Payen et al., 1993) Mitochondrial oxidative capacity can be affected by both blood 
flow to the skeletal muscle and oxygen partial pressure. 
In pulmonary hypertension, the progressive increase in pulmonary vascular resistance to 
blood flow, leads to increase in right ventricle afterload and a decrease in cardiac output. 
(McLaughlin and McGoon, 2006) Patients with IPAH have impaired cardiac output at rest 
and during exercise due to impaired stroke volume augmentation and chronotropic 
incompetence. (Holverda et al., 2006, Riley et al., 2000) This leads to a decrease in systemic 
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oxygen delivery to peripheral tissues including the skeletal muscle. In IPAH there is impaired 
muscle angiogenesis, capillarisation and microcirculatory alterations that can affect local 
oxygen delivery. (Potus et al., 2014, Dimopoulos et al., 2013b) The recovery kinetics of PCr 
is dependent on extra-mitochondrial factors including oxygen delivery, therefore not 
representative purely of muscle mitochondrial capacity. (Kemp, 2004) Impaired oxygen 
delivery either due to central or peripheral haemodynamics to the skeletal muscle can affect 
PCr recovery times. (Kemps et al., 2010, Kemp, 2004) In chronic heart failure, prolonged PCr 
t1/2 is associated with decreased recovery kinetics of deoxygenated haemoglobin in the post-
exercise period, suggesting inadequate oxygen delivery rather than oxygen utilization as the 
cause of exercise intolerance. (Kemps et al., 2010) Furthermore, the literature values of PCr 
t1/2 in mitochondrial myopathy is more prolonged, between 64-92seconds, although these 
were performed in different muscle groups using different 31P-MRS protocol. (Taylor et al., 
1994) Therefore, the delayed PCr t1/2 times observed in this study is due to impaired oxygen 
delivery rather a primary mitochondrial dysfunction. 
In the current study, there is evidence of abnormal muscle acid handling in IPAH with 
significantly lower pH during exercise and prolonged pH recovery times after exercise. At 
low intensity exercise, intracellular pH control is predominantly by sodium/proton antiporters. 
(Juel, 1998) PCr recovery times can be affected by pH and end-exercise conditions, whereas 
ADP recovery times is less affected. (Argov et al., 2000) There was no significant difference 
in ADP recovery time compared to healthy controls in the current study. Moreover, in 
mitochondrial myopathy the rate of recovery of pH is faster than healthy patients due to 
upregulation of proton efflux, further supporting the argument of impaired oxygen delivery 
rather than mitochondrial dysfunction as the cause of prolonged PCR t1/2 in IPAH patients. 
(Taylor et al., 1994) The rapid proton efflux allows for a high concentration of ADP in the 
presence of lactic acid production without depleting PCr in primary mitochondrial diseases. 
(Taylor et al., 1994, Chen et al., 2001). In primary biliary cirrhosis there is abnormal 
peripheral muscle pH handling after exercise with impaired proton efflux, which is associated 
with perceived fatigue levels. (Hollingsworth et al., 2008) Studies have suggested that 
autonomic nervous system play a role in acid handling by driving the sodium/proton 
antiporter. (Kemp et al., 1997, Syme et al., 1991). In chronic fatigue syndrome, there is 
association between autonomic dysfunction and abnormal pH handling. (Jones et al., 2010) 
Certainly, in IPAH there is evidence of impaired autonomic dysfunction associated with 
exercise capacity. (Wensel et al., 2009) Although the muscle pH handling is a complex 
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process, the question arises as to whether autonomic dysfunction affects muscle pH handling, 
and perceived fatigue experienced by pulmonary hypertension patients.  
3.5 Limitations 
The current study has a number of limitations. This was a pilot study, hence the number of 
participants recruited were small, and therefore should be cautious in our interpretation of the 
findings. The study cohort was a very specific group within pulmonary hypertension with 
relatively mild disease (n = 5 in WHO-FC 2). Patients on intravenous therapy by definition 
have severe disease could not be studied due to the intravenous pump being ferromagnetic. 
The results cannot necessarily be extrapolated to other patient groups with pulmonary 
hypertension of differing aetiology and severity.  Skeletal bioenergetics was studied in the 
supine position in response to submaximal exercise and therefore interpreting 31P-MRS 
results in view of skeletal muscle bioenergetics in whole-body exercise is difficult. (Kemps et 
al., 2010) Whilst the 31P-MRS is used for research purposes to assess mitochondrial function 
due to its inherent advantage of being non-invasive, there is limited application of this 
technique to detect mitochondrial myopathies in the clinical environment due to a lack of 
sensitivity. (Jeppesen et al., 2007) Although the assumption is PCr recovery is due to 
oxidative ATP synthesis, a small component of this recovery is due to the glycolytic pathway. 
(Vinnakota et al., 2006, Forbes et al., 2009) As discussed earlier, mitochondrial oxidative 
capacity as assessed by PCR t1/2 can be affected by blood flow and arterial oxygen content. 
3.6 Clinical Perspective 
The study lends support to the notion that PH is a multi-systemic disease, with implications 
beyond the pulmonary vasculature. The impaired skeletal muscle bioenergetics is due to lack 
of oxygen delivery. Thus, the individual patient needs a more holistic approach to treatment, 
with a greater explanation of the impact the disease will have of them. In clinical practice, PH 
patients report observationally significant peripheral muscle fatigue on exertion. This could be 
due to impaired acid handling in the muscle that was observed in current study and these 
patients may benefit from focused resistance exercise training.  
The study should stimulate further work on understanding the mechanisms of skeletal 
bioenergetics, exercise intolerance and muscle fatigue in pulmonary hypertension. Assessing 
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central and peripheral factors affecting local oxygen delivery during exercise should also be 
explored. This can include right heart catheterisation or cardiac magnetic resonance scans 
whilst undertaking supine aerobic or resistance exercises. Near-infrared spectroscopy (NIRS) 
simultaneously with 31P-MRS scan or during measuring central haemodynamics allows for 
the possibility of determining local oxygen kinetics during and after exercise. (Kemps et al., 
2010). Moreover, further work should explore the possibility of improving muscle 
performance and fatigue in pulmonary hypertension with focused resistance exercise training.  
3.7 Conclusions 
In summary, there is evidence of abnormal skeletal muscle bioenergetics in IPAH patients. 
The prolonged PCr recovery is secondary to impaired oxygen delivery rather than primary 
mitochondrial dysfunction.  IPAH patients showed abnormal handling of muscle intracellular 
acidosis during exercise, a pattern inconsistent with mitochondrial dysfunction and could be 
contributing to perceived muscle fatigue on exercise. Further studies are needed to carefully 
examine factors affecting oxygen delivery during and after exercise that can affect exercise 
intolerance and be contributing to muscle fatigue in IPAH patients. 
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Chapter 4 In Vitro Skeletal Muscle Mitochondrial Function in Idiopathic 
Pulmonary Arterial Hypertension 
4.1 Introduction 
The clinical spectrum of IPAH extends beyond the pulmonary vasculature and cardiac 
function.  Patients suffer from iron-deficiency, skeletal myopathy and increased prevalence of 
co-morbidities of increasing age at diagnosis contributing to exercise intolerance. (Ruiter et 
al., 2015, Panagiotou et al., 2015, Ling et al., 2012) Improvement in functional status and 
exercise capacity with targeted treatments including phosphodiesterase 5 inhibitors, 
endothelin receptor antagonists and prostacyclin analogues corresponds with better long-term 
prognosis. (Barst et al., 2013) Understanding the cellular and molecular processes affecting 
exercise capacity are crucial in the development future novel therapies. 
Mitochondria are the key organelles for the generation of energy in the form of adenosine 
triphosphate (ATP) using oxygen. Oxidative phosphorylation (OXPHOS), otherwise known 
as the respiratory electron transport chain, is the main mechanism by which ATP is generated 
through series of complexes creating an electrochemical gradient. (Freund-Michel et al., 
2014) The mitochondria can initiate apoptosis and provide metabolites for the proliferating 
cell. (Zamzami and Kroemer, 2001). In the pulmonary arteries, the mitochondria act as 
oxygen sensors and has a role in mediating hypoxic pulmonary vasoconstriction. (Ward and 
McMurtry, 2009) There is evidence of metabolic dysfunction in the pulmonary vasculature 
with \impaired mitochondrial function contributing to the pathobiology of pulmonary 
hypertension. (Paulin and Michelakis, 2014) 
Mitochondrial dysfunction in the pulmonary artery contributes to the proliferation and 
impaired apoptosis of pulmonary artery smooth muscle (PASMC) and endothelial cells 
(PAECC). (Archer et al., 2013) . The mitochondrial-reactive oxygen species (ROS) – HIF-1α-
Kv1.5 oxygen sensing pathway is altered.  There is decreased superoxide dismutase 2 (SOD2) 
levels leading to reduced ROS production, contributing to increased hypoxia inducible factor-
1α (HIF-1α) levels, despite the presence of adequate oxygen. (Archer et al., 2010) This 
ultimately results in inhibition of pyruvate dehydrogenase (PDH), and with downregulation in 
the expression of Kv1.5 potassium channel. (Bonnet et al., 2006) As a result, there is calcium 
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overloading and depolarisation of the PASMCs. The altered mitochondrial metabolism and 
dynamics leads to apoptotic impairment and proliferation of PASMC.  
Skeletal muscle mitochondrial dysfunction appears to contribute to exercise intolerance in 
patients with proven mitochondrial myopathy. (Taivassalo et al., 2003) Skeletal muscle 
mitochondria in IPAH have reduced ability to undergo fusion with downregulation of 
mitofusin 1 and 2 suggesting this may contribute to muscle atrophy and mitochondrial 
inefficiency. (Batt et al., 2014) Malenfant et al, using proteomic analysis highlighted nine 
proteins of  skeletal muscle that were down regulated including subunits of complex I, III and 
V of the mitochondrial OXPHOS pathway. (Malenfant et al., 2015) The authors concluded 
that mitochondrial dysfunction found in the pulmonary vasculature was also evident in the 
skeletal muscle of patients with IPAH, contributing to their exercise intolerance. 
The primary aim of this study is to objectively assess skeletal muscle mitochondrial oxidative 
phosphorylation protein expression and function in IPAH. The secondary aims are to 1) To 
determine structural morphology of the skeletal muscle in IPAH, and 2) To assess any 
association between exercise capacity, fatigue severity, quality of life and skeletal 
mitochondrial OXPHOS function.  
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4.2 Patients and Methods 
4.2.1 Study design  
This was a cross-sectional, pilot study. Nine participants with IPAH were recruited from the 
National Pulmonary Hypertension Service (Newcastle). IPAH diagnosis were made on results 
of right heart catheterisation of mean pulmonary artery pressure ≥ 25mmHg, mean pulmonary 
capillary wedge pressure ≤ 15mmHg with an elevated pulmonary vascular resistance > 3 
Wood units. All participants completed two questionnaires (emPHasis-10 and Fatigue 
Severity Scale) and underwent a vastus lateralis skeletal muscle biopsy was obtained. Clinical 
characteristics including age, gender, World Health Organization functional class (WHO FC), 
body mass index (BMI), cardiopulmonary haemodynamics, 6MWD and current treatments 
were collected.  
All patients were on anticoagulation (warfarin) that was stopped two weeks prior to the 
biopsy, with international normalized ratio (INR) checked 1-2 days before the biopsy. The 
study was approved by the local research ethics committee (Newcastle and North Tyneside 2: 
13/NE/0353). All patients gave written informed consent to participate in the study.  
The primary outcome is the expression of subunits of complex I and IV after adjustment for 
mitochondrial mass. The secondary outcomes are skeletal muscle histology, mitochondrial 
OXPHOS histochemical analysis, exercise capacity, quality of life, and fatigue severity. 
4.2.2 Inclusion and exclusion criteria 
Inclusion Criteria: 
- Patients’ aged greater than 18 years and less than 75 years; 
- Underlying diagnosis of IPAH confirmed by the Northern Pulmonary Vascular 
Service; 
- Clinically stable and compensated on medical therapy for at least 3 months;  
- World Health Organization (WHO) functional Class II to IV. 
Exclusion Criteria 
- Patients who are unable to provide informed consent; 
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- Patients on steroid therapy – as these drugs are known to cause myopathy; 
- Patients with recent syncope;  
- Patients with known skeletal muscle abnormalities; 
- Patients with ischaemic heart disease. 
- Patients with claustrophobia; 
- Patients with active cancer; 
 
4.2.3 Cardiopulmonary exercise testing 
Each participant completed symptom-limited CPEX exercise testing using a step-protocol 
with breath-by-breath gas analysis was performed at rest and during exercise in all studies 
(Medgraphics, St Paul, MN, USA) to measure oxygen consumption. Six participants 
underwent non-invasive central haemodynamics measurements continuously throughout the 
test. (NICOM®) 
Peak VO2 was highest O2 uptake, averaged over last 30 seconds of exercise.  Arterio-venous 
oxygen content difference (AVO2 diff ) was obtained indirectly using the Fick method as the 
ratio between VO2 and CO.  
4.2.4 Muscle biopsy 
All participants underwent muscle biopsy at the Clinical Research Facility, Royal Victoria 
Infirmary, Newcastle. Aseptic technique using modified ethmoid needle was employed to 
obtain 2-3 pea sized muscle biopsies from the vastus lateralis. The biopsies were snap frozen 
in liquid nitrogen and stored at -80oC. 
Cryostat was used at -20oC, to cut transversely orientated sections at 10µM thickness onto 
positively charged Superfrost® slides and air dried for 1 hour. The slides were then stored at        
-80oC. 
4.2.5 Laboratory analysis 
All muscle biopsies underwent initial screening analysis of basic structure and mitochondrial 
oxidative phosphorylation function using non-quantitative method. This included structural 
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analysis of muscle samples using haematoxylin/eosin (HE) staining and modified Gomori 
trichrome. Using histochemistry, analysis for complex II (succinate dehydrogenase, SDH), 
complex IV (cytochrome C oxidase, COX) and combined SDH/COX to determine  
mitochondrial OXPHOS dysfunction was determined. Images were analysed using a modified 
light microscope (Olympus, Japan) with a motorized stage. These techniques are described in 
further detail in chapter 2 and performed with aid from Mr Gavin Falkous. (Old and Johnson, 
1989, Reichmann et al., 1996) 
In order to accurately corroborate the findings, quadruple immunofluorescence was 
performed. Primary antibodies to detect complex I (NDUFB8), complex IV (COX-1), 
mitochondrial mass (porin) and delineate muscle myofibre boundaries (laminin) was used. 
Each patient sample had a muscle section for no-primary antibody controls (NPC), incubated 
with anti-laminin antibody only. Image acquisition was performed and acquired at ×20 
magnification using a Zeiss Axio Imager M1 and Zen 2011(blue edition) software. Further 
details are described in chapter 2. (Rocha et al., 2015) 
4.2.6 Statistical analysis 
Analyses were performed using R 3.1.3 program to generate z-values for the protein 
expression of COX-1 and NDUFB8 subunits after adjustment for mitochondrial mass. R-
program coded by Dr John Grady. (Rocha et al., 2015) Mitochondrial respiratory chain 
expression profile plots were generated using GraphPad Prism Version 5.02®. Full details of 
analysis are described in chapter 2.  
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4.3 Results 
4.3.1 Baseline characteristics 
Individual patient clinical and exercise capacity characteristics are shown in Table 4. 
4.3.2 Skeletal muscle mitochondrial OXPHOS function 
Initial histochemical analysis determined the function of complex II (SDH) and IV (COX). 
(Old and Johnson, 1989) Observational analysis of the muscle sections showed normal 
function of complex II and IV. The COX/SDH sequential staining show COX-deficient fibres 
as blue.  All patients had less <1% fibres that were COX-ve, which were within normal range. 
(Figure 13) 
In order to corroborate our results quadruple immunofluorescence was undertaken. The 
results compared to healthy and disease control samples, showed normal expression of 
subunits of complex I and IV in the majority of myofibres analysed after adjustment for 
mitochondrial mass. The expression profiles of all patients including control samples are 
shown in figures 14-17. 
4.3.3 Structural morphology in skeletal muscle 
Haematoxylin and eosin sections were visually inspected, with all nine samples demonstrating 
peripheral position of nuclei, with no necrosis of myofibres, absence of inflammatory cells 
with no basophilic granularity. There was no accumulation of adipose tissue, fibrosis or 
longitudinal fibre splitting. 
Gomori trichrome failed to demonstrate any myofibres with ragged-red appearance or rimmed 
vacuoles in all nine patients. Ragged-red fibres are seen in primary mitochondrial myopathies 
due to sub-sarcolemmal peripheral accumulation of abnormal mitochondria. (Old and 
Johnson, 1989) 
4.3.4 Exercise capacity, fatigue severity and quality of life  
Nine participants had a 6MWD between 374-520 metres. They demonstrated peak oxygen 
consumption (VO2) between 38-84% of predicted value (10 -19 ml/kg/min). In six patients 
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central haemodynamics were measured. Cardiac index at peak exercise varied between 4.4-
9.2 L/min/m2 with peripheral oxygen extraction at peak exercise 9.2-12.8 ml O2/dl. There was 
a significant association between fatigue severity and quality of life (r2=0.486, p = 0.037, 
Figure 12). Three patients reported severe fatigue levels (FSS>4). (Table 5) 
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Table 4: Baseline characteristics.  
Patient Age/Gender BMI 
(kg/m2) 
WHO FC mPAP 
(mmHg) 
CO 
(L/min) 
CI 
(L/min/m2) 
PVR 
(Wood units) 
Treatment BMPRII 
status 
1 29F 39 3 42 5.9 2.5 6.4 PDE5i + 
2 52M 32 2 20 6.8 3.0 2.5 PDE5i - 
3 38F 18 3 45 3.8 2.5 10.5 IV prostacyclin - 
4 31F 20 3 65 5.6 3.0 10.0 IV prostacyclin - 
5 67M 33 2 46 4.0 2.1 10.5 PDE5i and IV 
prostacyclin 
- 
6 48F 28 2 31 7.5 4.1 2.3 PDE5i and 
ERA 
- 
7 69F 26 2 46 4.0 2.5 10.1 ERA - 
8 40M 28 2 37 4.8 2.5 6.8 PDE5i + 
9 43F 24 2 33 4.9 2.8 5.1 PDE5i and 
ERA 
- 
Abbreviations: BMI – body mass index, WHO FC – world health organization functional class, mPAP – mean pulmonary artery pressure, CO – 
cardiac output, CI – cardiac index, PVR – pulmonary vascular resistance, BMPRII – bone morphogenetic protein receptor type II mutation, PDE5i 
– phosphodiesterase type 5 inhibitor, ERA – endothelin receptor antagonist, IV prostacyclin- intravenous prostacyclin (iloprost) 
 
67 
 
Table 5: Quality of life, fatigue severity and exercise capacity for each patient 
Patient EmPHasis-10 Fatigue 
Severity Scale 
6MWD 
(m) 
Peak VO2 
(ml/kg/min) 
Predicted 
(%) 
Peak CO 
(L/min) 
Peak CI 
(L/min/m2) 
AVO2 diff (ml O2/dl) 
1 35 3.88 420 10.0 52    
2 6 2.88 402 14.5 57 16.6 7.0 9.9 
3 28 3.22 423 12.5 41    
4 26 5.44 520 14.8 38 10.9 5.8 9.2 
5 29 4.77 396 10.8 69    
6 29 4.88 374 18.2 84 12.7 7.0 10.8 
7 7 1.00 376 12.9 63 7.3 4.4 11.5 
8 29 6.00 520 18.9 61 17.8 9.2 9.0 
9 25 5.33 455 16.2 65 8.6 5.2 12.8 
Abbreviations: 6MWD – six-minute walk distance, peak VO2 – peak oxygen consumption, CO – cardiac output, CI – cardiac index                        
AVO2 diff – arterio-venous oxygen difference 
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Figure 12: Scatter plot with trendline to demonstrate the association with quality of life 
assessed by standardised questionnaire for pulmonary hypertension (emPHasis-10) and 
fatigue severity (FSS).  
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Figure 13: Example of histology and histochemistry slides from an IPAH patient at ×20 
magnification.  
Structural assessment of skeletal muscle by haematoxylin/eosin staining (H & E) and Gomori 
trichrome (GT). Histochemistry assessed respiratory chain function of complex II (succinate 
dehydrogenase, SDH), complex IV (cytochrome C oxidase, COX), and sequential COX/SDH 
staining. In COX/SDH staining slides, COX deficient fibres will appear blue. 
H & E 
COX/SDH 
GT 
COX 
SDH  
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Figure 14:  Representative images from quadruple immunofluorescence.  
Complex I and IV abundance in skeletal muscle from healthy control, IPAH patient and disease control. Images acquired through fluorescent detection: 
COX –I – green, NDUFB8 – purple, porin – red and laminin – white.  
 
 
 Laminin  COX-I  NDUFB8  Porin  Overlay
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Figure 15.  Mitochondrial oxidative phosphorylation respiratory chain expression profile, linking complex I, complex IV and porin levels in 
patients.  
(A) Healthy control, 51F (n = 318) (B) Healthy control, 49M (n = 238) and (C) Disease control, 60M (n= 188). As described before by Rocha et al, 
each dot represents the measurement from individual muscle fibre, colour coded according to its mitochondrial mass (very low: blue, low: light blue, 
normal: light orange, high: orange and very high: red). The x and y axis indicate the levels of complex I and IV, respectively, in standard deviations. 
Colours on the axis indicate levels of deficiency: beige: normal, light beige: intermediate (+), light blue: intermediate (-) and blue: deficient. The 
number (n) in brackets gives the number of myofibres analysed for each patient. 
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Figure 16: Plots show complex I and IV expression in patients with IPAH.  
(D) Patient 1 (n = 166) (E) Patient 2 (n = 514) (F) Patient 3 (n = 497) 
 
73 
 
Figure 17: Continuation of Figure 14.  
Plots show complex I and IV expression in patients with IPAH. (G) Patient 4 (n = 317) (H) Patient 5 (n = 449) (I) Patient 6 (n = 394) 
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Figure 18: Continuation of Figure 14.  
Plots show complex I and IV expression in patients with IPAH. (J) Patient 7 (n = 431) (K) Patient 8 (n = 405) (L) Patient 9 (n = 409) 
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4.4 Discussion 
This is the first study to objectively assess in vitro skeletal muscle mitochondrial OXPHOS 
capacity and function in IPAH. The study shows 1) there is normal skeletal muscle 
mitochondrial OXPHOS protein expression and function 2) no gross structural abnormality 
noted on visual assessment of the skeletal muscle 3) IPAH patients demonstrated 
heterogeneous exercise capacity, peak cardiac index, quality of life and fatigue severity in 
patients with consistently normal skeletal muscle mitochondrial function.  
Using the two laboratory methods, data revealed that IPAH patients have normal skeletal 
muscle mitochondrial OXPHOS function.  Quadruple immunofluorescence is a new state-of-
the-art technology that accurately quantifies expression of subunits of complex I and IV with 
adjustment for mitochondrial mass. In comparison to current histochemical methods, 
advantages of immunofluorescence includes the avoidance of subjective assessment of 
mitochondrial dysfunction, the presence of tissue-specific artefacts leading to uneven 
labelling and individual assessment of all myofibres in a given transverse cross-section of 
muscle biopsy. (Rocha et al., 2015) In IPAH, skeletal muscle oxidative enzyme expression 
has been shown to be reduced, with an association between exercise capacity and muscle 
contractile strength. (Mainguy et al., 2010) In animal models, expression of genes involved in 
mitochondrial biogenesis within the skeletal muscle was decreased earlier than in 
cardiomyocytes from the right ventricle during the disease course (Enache et al., 2013) In PH 
patients, skeletal muscle mitochondria has diminished ability to undergo fusion with reduced 
levels of mitofusin 1 and 2. (Batt et al., 2014) Skeletal muscle mitochondrial content and 
biogenesis were assessed to be similar between IPAH and healthy controls. (Batt et al., 2014) 
Malefont et al, suggested mitochondrial dysfunction evident in the pulmonary vasculature 
was also present in the skeletal muscle of IPAH patients and contributing to their exercise 
intolerance. First, they showed decreased mitochondrial density using electron microscopy 
and second, demonstrated downregulation of subunits of complexes I, III and IV by 
proteomic analysis. The methodology used , proteomic analysis, has a number of limitations 
including lacking specificity and values obtained were unable to be adjusted for mitochondrial 
mass. The current study results indicate  that one of the reasons for exercise intolerance in 
IPAH is not due to skeletal muscle mitochondrial OXPHOS ability to generate ATP during 
exercise. The findings are corroborated by the ex vivo results of 31P-MRS in chapter 3, where 
the obtained data pattern would be inconsistent with the presence of a true skeletal muscle 
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mitochondrial dysfunction.  These results supports the assertion that factors further upstream 
along oxygen transport pathway, rather than oxygen utilization, are responsible for impaired 
exercise capacity in IPAH. 
The oxygen transport pathway from the air to the skeletal muscle mitochondria is a complex 
system. There are number of potential mechanisms that can affect oxygen delivery to the 
muscle mitochondria in IPAH including central and peripheral factors. (Wagner, 2012)  
Central factors include chronotropic incompetence and impaired stroke volume augmentation 
during exercise affects peak VO2. (Holverda et al., 2006, Fowler et al., 2012). At the skeletal 
muscle level, there is evidence of reduced capillarisation, angiogenesis and abnormal 
peripheral microcirculation. (Mainguy et al., 2010, Potus et al., 2014, Dimopoulos et al., 
2013a) During the onset of heavy exercise, there is an imbalance between oxygen delivery to 
utilization can lead to ATP generation through oxygen-independent pathway, by-products  of 
which could cause muscle fatigue.(Barbosa et al., 2011) All these factors can affect oxygen 
delivery to the exercising skeletal muscle and impairing exercise capacity. Furthermore, 
muscle ability to extract oxygen from the capillaries to the mitochondria through diffusion 
could be altered, but currently, there is limited understanding to what extent this plays a role 
in IPAH.  
Available therapies focus on predefined targets in the pulmonary artery known to be affected 
in IPAH including the nitric oxide, endothelin and prostaglandin pathways. (Humbert et al., 
2014) They work by reducing the resistance to blood flow by vasodilatation, therefore the 
afterload is decreased and resting cardiac output is increased. (Humbert et al., 2014) There is 
some evidence that targeted therapies in pulmonary hypertension improves cardiac output 
during  exercise but the effect on peripheral factors affecting oxygen delivery is unknown. 
(Provencher et al., 2008) The current study showed in clinically stable IPAH patients with 
variable peak oxygen consumption, cardiac output and peripheral oxygen extraction at peak 
exercise, all had normal ability to utilize oxygen in the skeletal muscle. (Table 5) 
Peak cardiac index achieved during symptom-limited cardiopulmonary exercise testing has 
been shown to be powerful prognostic marker of outcome. (Blumberg et al., 2013) Exercise 
training improves submaximal and maximal exercise performance beyond those achieved by 
medications in clinically stable patients. (Mereles et al., 2006) Resting central 
haemodynamics has been shown to improve with aerobic exercise training. (Ehlken et al., 
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2016) Muscle oxidative enzyme activity and capillarisation is improved by a combination of 
aerobic and resistance training. (de Man et al., 2009) Therefore it would seem exercise 
training is a potential way of targeting central and peripheral mechanisms of oxygen delivery 
to the skeletal muscle.  
4.5 Limitations 
The present pilot study is not without limitation. Being a pilot study the number of patients 
recruited was small, but the patient numbers are on par with published studies that focused on 
the skeletal muscle in IPAH, where 8-10 patients were recruited. (Mainguy et al., 2010, Batt 
et al., 2014, Malenfant et al., 2015) Furthermore for the main trial, recruiting patients in great 
numbers would be difficult due to invasive nature of the study, the use of anticoagulation for 
reasons beyond IPAH, and presence of co-morbidities will restrict numbers from any one 
pulmonary hypertension centre. The patients recruited were clinically stable and all were in 
WHO FC 2 or 3. Nevertheless, three of the patients were on intravenous therapy, including 
one patient who underwent lung transplantation within a year of the muscle biopsy. Therefore, 
the study recruited patients with a wide spectrum of disease severity and demonstrated 
consistent results in terms of primary outcome.  Skeletal muscle mitochondrial oxidative 
phosphorylation function could be affected by the aetiology causing pulmonary arterial 
hypertension and care should be sought if there was extrapolation of the current data beyond 
idiopathic cases. There is considerable inter-observer variability in terms of counting COX-ve 
fibres on the COX/SDH histochemistry sections. (Rocha et al., 2015) No attempt was made to 
quantify COX-intermediate fibres in COX/SDH sections due to the subjective nature of this 
assessment. (Murphy et al., 2012) However, the use of quadruple immunofluorescence 
supersedes the methodological flaws with the use of histochemistry. 
4.6 Clinical Perspective 
The current study raises a number of questions regarding exercise intolerance and fatigue in 
IPAH. There is a need to understand:  1) peripheral factors affecting oxygen delivery and 
extraction in the skeletal muscle during exercise 2) to what extent does this contribute to 
impaired exercise capacity beyond central haemodynamics and 3) how can fatigue be 
improved in daily clinical practice.  Although this study showed that skeletal muscle 
mitochondrial OXPHOS system is intact, there are still structural and functional changes 
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present that would affect physical performance and quality of life. The role of exercise 
training in maintaining or reversing changes in skeletal muscle requires further investigation. 
Aerobic training under supervision has been shown to be relatively safe; no study has focused 
purely on resistance training in maintaining physical conditioning in IPAH. (Grunig et al., 
2012a) Resistance training is known to increase protein synthesis, muscle hypertrophy and 
strength. (Damas et al., 2015)  Therefore research is needed into how the skeletal muscle will 
change at the molecular, structural and functional levels in response to resistance training in 
IPAH. This would stimulate further work into the safety, dose, and intensity of resistance 
training programmes that would prove beneficial. Resistance training would not be expected 
to lead to increased exercise capacity, but it may improve ability to perform activities of daily 
living, quality of life and decrease perceived muscle fatigue levels. 
4.7 Conclusions 
In vitro analysis of skeletal muscle in IPAH has showed normal protein expression and 
function of mitochondrial oxidative phosphorylation system. The study demonstrates that one 
of the reasons for diminished exercise capacity in IPAH is not due to primary mitochondrial 
OXPHOS dysfunction. These same patients in the study cohort demonstrated variable 
subjective and objective effects of the disease on their daily life including quality of life, 
fatigue and exercise capacity. Three patients where on intravenous treatment with one 
requiring lung transplantation within a year of their muscle biopsy. Further research is 
warranted into understanding peripheral factors affecting oxygen delivery and extraction in 
IPAH. This will hopefully stimulate research into potential treatments that target central and 
peripheral factors affecting oxygen transport to the muscle mitochondria.  
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Chapter 5 Central and peripheral limitations to exercise intolerance in 
pulmonary hypertension and the relationship with fatigue 
5.1 Introduction 
Pulmonary hypertension (PH) is marked by exercise intolerance that becomes progressively 
debilitating as the disease progresses. (McLaughlin and McGoon, 2006) Peak oxygen uptake, 
a marker of maximal exercise capacity, has been shown to be reduced in PH compared to 
healthy subjects and associated with poor prognosis. (Sun et al., 2001, Deboeck et al., 2012) 
Improving exercise capacity is a recognized target and clinical biomarker of response to PH 
targeted therapy.  Cardiopulmonary exercise stress testing aides in determining whether 
escalation of treatment is warranted. (Wensel et al., 2013, Paolillo et al., 2012)  
Understanding the physiological limitations of physical performance and oxygen 
consumption may allow a more targeted approach to therapy. According to the Fick principle, 
oxygen consumption (VO2) is determined by three components; (1) the stroke volume (SV), 
(2) heart rate (HR) and (3) arterio-mixed venous oxygen content difference (AVO2 diff). 
(Murias et al., 2013) In people without cardiorespiratory disease, in response to maximal 
exercise, VO2 increase is due to significant increases in heart rate and AVO2 diff, with a 
smaller percentage increase in stroke volume. (Higginbotham et al., 1986, Proctor et al., 1998) 
Studies of people with PH demonstrate evidence of chronotropic incompetence and impaired 
ability to augment stroke volume in response to exercise. (Holverda et al., 2006, Provencher 
et al., 2006a) PH is also associated with a number of skeletal muscle changes that may result 
in impaired peripheral oxygen extraction. (Panagiotou et al., 2015) Currently, whether 
peripheral oxygen extraction increases proportionately to exercise to compensate for impaired 
cardiac output or acts as another component limiting VO2 in pulmonary hypertension remains 
unclear. 
The primary aim of this pilot study is to determine central and peripheral factors that affect 
oxygen uptake and utilisation during upright symptom-limited exercise in patients with 
pulmonary hypertension compared to age- and gender-matched controls. The secondary aims 
are to 1) to determine central and peripheral reserve capacity from rest to peak exercise and 2) 
to determine association between patient-reported fatigue and quality of life with derived 
exercise parameters. 
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5.2 Methods 
5.2.1 Study population and design 
Eighteen patients with pulmonary hypertension (n=18) and eighteen people without 
cardiorespiratory disease took part in this study. Patients were recruited from the National 
Pulmonary Hypertension Service (Newcastle) and controls from ongoing studies from within 
the MoveLab team. All patients were able to undergo symptom-limited cardiopulmonary 
exercise testing. Patients with significant musculoskeletal disease or cardiopulmonary 
diseases including patients with coronary artery disease evident on coronary angiogram were 
excluded. None of the subjects were on supplemental oxygen.  
All participants underwent cardiopulmonary exercise testing (CPEX) with continuous non-
invasive gas exchange and central haemodynamic measurements. Patients also completed 
self-reported fatigue severity and quality of life questionnaires. Patients had up to date 6 
minute walk distance (6MWD), WHO functional class and N-terminal pro brain naturietic 
peptide (NT-proBNP). Most recent resting right catheter measurements were retrieved.  
Ethical approval was given by the local regional ethics committee (Westminister – 
15/LO/0144) and the study complies with the Declaration of Helsinki. 
The primary outcome measure was the AVO2 diff between the two study groups. Secondary 
outcome measures include difference in peak cardiac index, peak cardiac power output, the 
reserve capacity of the individual components of VO2 and correlation of exercise variables 
with patient-reported fatigue.  
5.2.2 Cardiopulmonary exercise testing 
Patients and controls undertook a progressive cycle test with termination limited by clinical 
symptom (patients) or self-terminated (patients/controls). Expired gases were collected to 
assess gas-exchange (Medgraphics, St Paul, MN, USA) and cardiac haemodynamic measures 
by bioreactance (NICOM®, Cheetah Medical, USA) at rest and during exercise.  
Bioreactance has been shown to be superior to other non-invasive methods of assessing 
cardiac output at rest and on exercise. (Jakovljevic et al., 2012a) Furthermore, at rest 
NICOM® has been correlated with thermodilution method in PH patients. (Rich et al., 2013) 
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The NICOM® determines the phase shift of current across the thorax using surface electrodes. 
After the skin is prepped, two electrodes placed in the upper torso and two over the lower 
torso. The sensors on either side generate signals that are integrated for final signal analyses. 
The NICOM® processing unit determines the phase shift (Δφ) between output signal relative 
to the input signal, reflecting blood flow changes in the aorta. The cardiac output is equivalent 
to C × VET × Δφdtmax, where C is the constant of proportionality, VET is the ventricular 
ejection fraction time.(Jones et al., 2015) The stroke volume is calculated from the cardiac 
output and heart rate. (Jones et al., 2015, Squara et al., 2007) 
Peak VO2 was highest O2 uptake, averaged over last 30 seconds of exercise.  AVO2 diff was 
obtained indirectly using the Fick method as oxygen consumption divided by cardiac output. 
Maximum predicted heart rate was defined as 220 minus age in years. Cardiac power output 
was obtained by multiplying the mean arterial blood pressure with cardiac output and a 
constant (0.002222) and gives a value in watts. (Jakovljevic et al., 2012c) Physiological 
reserves were calculated as the percentage change from resting to peak values divided by 
resting values of each component of oxygen uptake. (Dhakal et al., 2015) 
Further information on cardiopulmonary exercise testing and bioreactance technology is 
provided in Chapter 2. 
 
5.2.3 Fatigue severity and quality of life 
Each participant completed two questionnaires including fatigue severity scale (FSS) and 
quality of life (emPHasis-10) prior to exercise testing.(Yorke et al., 2014, Valko et al., 2008) 
Questionnaires were not completed by healthy controls.  
 
5.2.4 Statistical analysis 
SPSS version 22 (Chicago, IL) was used for statistical analysis. Normality of distribution of 
the data was assessed by the Shapiro-Wilk test. Continuous data are presented as mean ± 
standard deviation. Comparison between groups is by either unpaired 2-sample student t test, 
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Mann Whitney U test or chi-squared test. Correlation was assessed by Pearson or Spearman 
tests with 2-tail test for significance. Partial R2 values were obtained after adjustment for age 
and gender by multiple linear regression as described previously. (Dhakal et al., 2015)  P-
values less than 0.05 were considered significant. Post-hoc power analysis for the sample n = 
18 revealed statistical power of 71.4%.  
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5.3 Results 
5.3.1 Baseline characteristics 
Population characteristics of all PH (n = 18) and control subjects (n = 18) are listed in Table 
6. The two groups were well matched in terms of age, gender, weight, height and body 
surface area. All patients exercised beyond their respective anaerobic threshold and achieved 
respiratory exchange ratio greater than 1. Patients were established on clinical pulmonary 
hypertension targeted treatments. (Table 6) There were no adverse effects in any subjects 
during exercise testing. diff in patients.  
 
Table 7 and Table 8 show the resting and peak exercise characteristics of the two groups. 
Compared to control subjects, PH patients showed no significant difference in resting oxygen 
uptake or heart rate. (Table 7) Exercise capacity, assessed by peak VO2 was significantly 
reduced in PH group compared to control. (Table 8) 
5.3.2 Baseline and exercise haemodynamics 
At rest, PH patients demonstrated significantly lower mean arterial blood pressure, cardiac 
output, cardiac index, stroke volume, stroke volume index, cardiac power output and cardiac 
power output index. (Table 7) At peak exercise, there were significant difference in heart rate, 
mean arterial blood pressure, stroke volume index, cardiac output, cardiac index, cardiac 
power output and cardiac power output index, with patients not performing as well as 
controls. Stroke volume at peak exercise was not significantly different between PH and 
control subjects. (Table 8)  
 
  
84 
 
Table 6: Baseline Characteristics 
 PH Control p - value 
Age (years) 53 ± 15 49 ± 16 0.378 
Gender (M:F) 8:10 8:10 1.000 
Height (cm) 167 ± 10 168 ± 11 0.861 
Weight (kg) 72 ± 16 71 ± 11 0.795 
BSA (m2) 1.83 ± 0.25 1.82 ± 0.19 0.911 
PH subtype 
- IPAH 
- PoPH 
- PAH-CHD 
- CTEPH 
 
11 
1 
4 
2 
  
WHO FC 
- II 
- III 
 
10 
8 
  
NT-proBNP, pg/ml 
 
606 ± 758   
Haemoglobin (gm/dL) 
 
14.2 ± 1.0   
Haemodynamics§ 
- mPAP (mmHg) 
- sPAP (mmHg) 
- RAP (mmHg) 
- PCWP (mmHg) 
- PVR (Woods) 
- CO (L/min) 
- CI (L/min/m2) 
- SvO2, % 
 
41 ± 13 
69 ± 23 
4 ± 3 
6 ± 4 
8.4 ± 4.4 
4.7 ± 1.4 
2.6 ± 0.8 
68 ± 8 
 
  
Treatment* 
- PDE5i 
- ERA 
- Prostacyclin 
 
16 
4 
1 
  
*Three patients were on combination treatment of PDE5i and ERA or PDE5i and 
prostacyclin. § - right heart catheter data in n = 17, mean time from CPEX of 1.43 ± 0.84 yrs 
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Abbreviations. BSA – body surface area, IPAH – idiopathic pulmonary arterial hypertension, 
PoPH – portopulmonary hypertension, PAH-CHD – Pulmonary arterial hypertension 
secondary to congenital heart disease, CTEPH – chronic thromboembolic pulmonary 
hypertension, WHO FC – World Health Organization Functional class, NT-proBNP – N-
terminal pro Brain Naturietic peptide, mPAP – mean pulmonary arterial pressure, sPAP –
systolic pulmonary arterial pressure, RAP – right atrial pressure, PVR – pulmonary vascular 
resistance, CO – cardiac output, CI – cardiac index, SvO2- mixed venous oxygen saturation, 
PDE5i – phosphodiesterase type 5 inhibitor, ERA – endothelin receptor antagonist 
 
 
5.3.3 Peripheral oxygen extraction at rest and peak exercise 
At rest, PH patients had higher, but not statistically significant, AVO2diff compared to control 
subjects (5.6 ± 1.6 vs 4.8 ± 1.4 mL/dL, p = 0.134). At peak exercise, PH patients had a 
significantly lower AVO2 diff (9.3 ± 2.3 vs 12.4 ± 4.8 mL/dL, p = 0.012).  
There was a significant correlation between cardiac output and peak oxygen uptake in patients 
(r = 0.510, p = 0.031) and controls (r = 0.504, p = 0.028). There was no relationship between 
AVO2diff and peak oxygen consumption in patients (r = 0.265 p = 0.289) whilst controls 
demonstrated a strong relationship (r = 0.753, p < 0.001). At peak exercise, there was no 
correlation between mass-adjusted peak O2 and cardiac index (r = 0.248, p = 0.321) in PH 
patients. Ventilatory efficiency slope (VE/VCO2) showed trend in correlation with peak 
cardiac index (r = -0.458, p = 0.056) and cardiac power output (r = -0.483, p = 0.043) but with 
no relationship with stroke volume, heart rate and AVO2diff in patients. 
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Table 7: Resting metabolic and haemodynamic parameters 
Characteristics Control PH p-value 
O2 (L/min) 0.28 ± 0.84 0.25 ± 0.07 0.252 
O2 (L/min/kg) 4.12 ± 1.66 3.63 ± 0.86 0.273 
RER* 0.90 ± 0.05 0.82 ± 0.16 0.030 
VE (L/min)* 8.0 ± 1.7 11.3 ± 3.5 0.003 
HR (bpm) 68 ± 8 72± 12 0.297 
SBP (mmHg) 137 ± 15 127 ± 15 0.043 
DBP (mmHg) 84 ± 11 74 ± 12 0.019 
MAP (mmHg) 101 ± 9 92 ± 11 0.008 
CO (L/min) 6.0 ± 1.2 4.8 ± 1.0 0.002 
CI (L/min) 3.3 ± 0.5 2.6 ± 0.5 < 0.001 
SV (mL/beat) 89 ± 21 65 ± 17 0.001 
SVI (mL/m2) 49 ± 10 36 ± 8 < 0.001 
AVO2 diff (mL/dL) 4.8 ± 1.4 5.6 ± 1.6 0.134 
CPO (Watts) 1.36 ± 0.32 0.98 ± 0.21 < 0.001 
CPOI (Watts/m2) 0.74 ± 0.12 0.53 ± 0.10 <0.001 
*Control data based on n = 14.  
Abbreviations: O2 –oxygen uptake, RER – respiratory exchange ratio, VE – minute 
ventilation, HR – heart rate, SBP –systolic blood pressure, DBP – diastolic blood pressure, 
MAP – mean arterial blood pressure, CO – cardiac output, CI – cardiac index, SV – stroke 
volume, SVI – stroke volume index, AVO2diff – arterio-venous oxygen difference, CPO – 
cardiac power output, CPOI – cardiac power output index 
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Table 8: Peak exercise gas-exchange and haemodynamic variables 
Characteristics Control PH p-value 
O2 (L/min) 2.25 ± 1.05 1.01 ± 0.31 < 0.001 
O2 (L/min/kg) 25.3 ± 5.7 14.0 ± 3.3 < 0.001 
RER* 1.21 ± 0.08 1.10 ± 0.07 < 0.001 
VE (L/min)* 65.8 ± 22.0 51.9 ± 14.2 0.037 
VE/VCO2 slope* 28.7 ± 2.4 49.6 ± 14.2 <0.001 
BR (%)* 34.9 ± 4.6 37.3 ± 15.6 0.583 
HR (bpm) 163 ± 21 123 ± 24 < 0.001 
HR predicted (%) 95 ± 9 74 ± 14 < 0.001 
SBP (mmHg) 200 ± 14 148 ± 27 <0.001 
DBP (mmHg) 88 ± 16 93 ± 29 0.903 
MAP (mmHg) 125 ± 12 111 ± 26 0.046 
SV (mL/beat) 118 ± 41 95 ± 33 0.92 
SVI (mL/m2) 64.0 ± 17.4 52.1 ± 15.9 0.037 
CO (L/min) 18.4 ± 5.4 11.5 ± 4.0 <0.001 
CI (L/min/m2) 10.0 ± 2.2 6.2 ± 1.9 <0.001 
CPO (Watts) 5.21 ± 1.85 2.77 ± 1.06 < 0.001 
CPOI (Watts/m2) 2.81 ± 0.78 1.52 ± 0.55 <0.001 
AVO2 diff (mL/dL) 12.4 ± 4.8 9.3 ± 2.3 0.012 
ΔAVO2diff/ΔVO2 (min/dL) 4.0 ± 1.8 5.3 ± 3.6 0.193 
ΔCO/ ΔVO2 (L blood/L O2) 7.1 ± 3.6 9.8 ± 6.0 0.121 
* Control data based on n = 14.  
Abbreviations: O2 –oxygen uptake, RER – respiratory exchange ratio, VE – minute 
ventilation, BR – breathing reserve, HR – heart rate, SBP –systolic blood pressure, DBP – 
diastolic blood pressure, MAP – mean arterial blood pressure, CO – cardiac output, CI – 
cardiac index, SV – stroke volume, SVI – stroke volume index, AVO2diff – arterio-venous 
oxygen difference, CPO – cardiac power output, CPOI – cardiac power output index 
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5.3.4 Integrated response of exercise haemodynamics 
The reserve capacity of each component of VO2 was assessed compared to resting values in 
percentages. In healthy controls, peak VO2 increased by 679 ± 247 %. This increase was due 
to changes in heart rate of 141 ± 36%, stroke volume 34 ± 42% and AVO2 diff 162 ± 79%. In 
PH subjects, peak VO2 increased by 308 ± 120% due to increase in heart rate of 72 ± 32%, 
stroke volume 48 ± 52% and AVO2 diff of 78 ± 62%. In both healthy controls and PH 
patients, the increase in AVO2 difference made significant contribution to the increase in VO2, 
with the percentage increase being the largest of the three components of VO2. (Figure 19) 
There was correlation in absolute change in cardiac output as a function of oxygen uptake and 
was on par with controls, whereas there was no correlation between absolute increases in 
ΔAVO2diff as a function of oxygen uptake in PH patients in comparison to controls. (Figure 
20) 
Partial R2 values were obtained for each component of peak VO2, including heart rate, stroke 
volume and AVO2 diff after adjusting for age and gender.  In healthy controls, peak VO2 was 
related to AVO2 diff (R
2 = 0.397, p = 0.028) but heart rate (R2 = 0.151, p = 0.211) and stroke 
volume (R2 = 0.05, p = 0.467) were not significant at maximum exercise. In PH patients, peak 
VO2 was related to peak HR (R
2
 = 0.284, p = 0.033), with a non-significant trend towards 
association with AVO2 diff (R
2=0.212, p = 0.073) and no association with SV (R2 < 0.001, p 
= 0.922). 
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Figure 19:  The increase from baseline to peak exercise in percentage of VO2 and each of 
its components in PH and control subjects.  
A) VO2   B) heart rate C) stroke volume and D) AVO2 difference.  * P-value less than 0.05. 
 
 
5.3.5 Fatigue, quality of life and exercise haemodynamic in PH 
Patient quality of life and fatigue were significantly correlated (r = 0.806, p < 0.001).  Quality 
of life scores did not correlate significantly with any of the peak exercise parameters. In the 
18 PH patients, severe fatigue as deemed by FSS score >4 was evident in 11 with a mean of 
4.3 ± 1.5. Fatigue levels showed significant negative correlation with percentage predicted 
heart rate (r = -0.474, p = 0.047) and peak AVO2 diff (r = -0.542, p = 0.020).   After adjusting 
for age and gender, only AVO2 diff remained negatively correlated with fatigue (r = -0.645, p 
= 0.007).  There was no significant correlation between fatigue scores and 6MWD, peak 
oxygen uptake, cardiac output, cardiac index, and NT-proBNP. 
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Figure 20:  Change in cardiac output (ΔCO) as a function of oxygen uptake (ΔVO2).  
This showed steeper increase in PH patients (solid line, p = 0.042) than controls (dashed lines, 
p = 0.042).
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Figure 21: Change in arterio-venous oxygen difference (AVO2 diff) as a function of 
oxygen uptake (ΔVO2)   
 
 
This demonstrates that in PH patients (solid line, p = 0.350) have a less relative increase 
compared to controls (dashed line, p <0.001) 
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5.4 Discussion 
In this study, continuous haemodynamic response to upright exercise was assessed using non-
invasive methodology in pulmonary hypertension. The study showed that PH patients in 
comparison with matched healthy controls demonstrate 1) impaired central cardiac output 
response to exercise predominantly due to chronotropic incompetence, 2) impaired peripheral 
oxygen extraction despite reduced cardiac output at peak exercise, 3) lack of association 
between change in peak oxygen uptake and change in peripheral oxygen extraction, 4) that 
fatigue severity was associated with peak peripheral oxygen extraction. These findings 
suggest the potential important role of targeting peripheral limitations in PH to augment 
aerobic exercise capacity beyond central cardiac limitations. 
Compared to healthy controls, PH patients had significant impairment in maximum exercise 
capacity as shown by reduced peak oxygen uptake. (Table 8) Pulmonary hypertension is 
marked by progressive exercise intolerance affecting quality of life and daily activity levels. 
(Fowler et al., 2012, Pugh et al., 2012) The body mass-adjusted peak VO2 achieved in the 
current study is similar to reported literature values for PH patients, with a mean respiratory 
exchange ratio of 1.10 suggesting our patients exercised to exhaustion. (Deboeck et al., 2012, 
Sun et al., 2001, Ferreira et al., 2014). Peak VO2 achieved on maximum exercise is 
determined by number of factors including cardiac output, peripheral oxygen extraction, 
patient effort or musculoskeletal problems. The strength in the current study is that stress 
testing was performed in the upright position with continuous measurement of cardiac output 
allowing for assessment of aerobic exercise capacity. Therefore, the relative contribution of 
the different components of oxygen uptake from rest to peak exercise was analysed to 
determine the factors affecting exercise intolerance in PH patients. 
The study demonstrates impaired peak cardiac output in both absolute values and adjusted for 
body surface area. Using the NICOM®, the relative contribution of heart rate and stroke 
volume were able to be assessed from rest to peak exercise. There was evidence of 
chronotropic incompetence at peak exercise compared to controls, with impaired heart rate 
reserve. None of the patients were on beta blockers. Stroke volume index at rest and peak 
exercise were significantly lower in PH patients but there was no significant difference in 
relative percentage increase in stroke volume between the two groups from rest to peak 
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exercise. The study suggests impaired ability to augment heart rate in PH patients with 
exercise has the most significant contribution to cardiac output. 
In previous studies, both chronotropic incompetence and lack of stroke volume augmentation 
in response to exercise limits cardiac output in PH. (Holverda et al., 2006) PH is associated 
with sympathetic over activity with impaired cardiac autonomic control that correlates with 
disease severity. (Wensel et al., 2009) Moreover, impaired recovery of heart rate after 
exercise has been associated with a worse exercise capacity and predictive of clinical 
deterioration. (Minai et al., 2012, Ramos et al., 2012) The significant difference in percentage 
increase in heart rate from rest to peak exercise between the groups as opposed to percentage 
increase in stroke volume suggest chronotropic incompetence is the predominant factor 
limiting cardiac output response to exercise in PH. (Figure 19). In support, withdrawal of 
beta-blockers in patients with portopulmonary hypertension leads to improved exercise 
capacity with increase in resting cardiac output driven by the rise in heart rate. (Provencher et 
al., 2006b) Studies have shown in PH, there is impaired ability of the right ventricle (RV) to 
increase contractility in response to submaximal exercise. (Spruijt et al., 2015) This has raised 
the possibility of whether inotropic medications will be ineffective and suggests that 
investigations into preventing maladaptive changes in the right ventricular are important in 
order restore contractility. (Spruijt et al., 2015) The impaired right ventricular contractile 
reserve and chronotropic incompetence could both be due to downregulation beta-
adrenoreceptors in the myocardium in PH patients. (Bristow et al., 1992) The evidence 
suggests developing treatments that prevent right ventricular maladaptation and restoring 
chronotropic response to exercise would result in improved aerobic exercise capacity in PH.  
Peripheral oxygen extraction (AVO2 diff) was significantly reduced at peak exercise in PH 
patients compared to controls. Furthermore, the percentage increase in AVO2 diff was 
significantly lower in PH subjects from rest to peak exercise.  AVO2 diff is a function of 
oxygen content and systematic oxygen extraction. Oxygen content in the blood is dependent 
on the haemoglobin level, oxygen saturation and partial pressure of oxygen. The current study 
findings are supported by previous evidence of impaired systematic oxygen extraction in PH 
patients using invasive methods in comparison to patients with left ventricle systolic 
dysfunction. (Tolle et al., 2008)  
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There are a number of potential explanations for these findings in this current study. 
Peripheral oxygen extraction is dependent on first, convective oxygen delivery to skeletal 
muscle, then passive diffusion of oxygen from the capillary to skeletal muscle mitochondria 
along a pressure gradient. (Wagner, 2012) Abnormalities present in skeletal muscle 
morphology and enzyme activities could in part, potentially explain the reduced AVO2 diff 
including muscle fibre type switch, reduced enzyme oxidative capacity, decreased capillary to 
fibre ratios, alteration in pathways favouring protein breakdown leading to muscle atrophy 
and impairment in electrical-contraction coupling affecting muscle contractility. (Mainguy et 
al., 2010, Batt et al., 2014) Factors affecting oxygen diffusion from the capillaries to the 
muscle mitochondria may also determine in part reduced peripheral oxygen extraction as 
observed in heart failure with preserved ejection fraction. (Dhakal et al., 2015). The increased 
sympathetic activity observed in many PH patients, could lead to increased local muscle 
vasoconstrictor activity and impaired vasodilation required during exercise to accommodate 
the increased blood flow to skeletal muscle during peak exercise. In support of this, there is 
evidence of impaired skeletal muscle microcirculation present in PH. (Dimopoulos et al., 
2013a) Another possible explanation is that potentially PH subjects could have terminated 
exercise prematurely before maximum peripheral oxygen extraction is achieved. All our 
patients demonstrated RER > 1.0 and the body-weight adjusted peak VO2, which was similar 
to previous studies in PH. (Sun et al., 2001, Ehlken et al., 2016) Furthermore, the increase in 
AVO2 diff with exercise is hyperbolic in both genders with increasing VO2 values therefore 
the relative contribution to the absolute values obtained is likely to be minimal if there was 
poor effort.(Murias et al., 2013, Tolle et al., 2008) The mean haemoglobin in PH subjects was 
14.2 ± 1.0gm/dL suggesting there was no evidence to suggest anaemia to confound the 
results.  Due to the non-invasive nature of the study, direct measurement of oxygen saturation 
and partial pressure was not possible during exercise and must be factored into the 
interpretation of the results. However, within the population of patients with LV systolic 
dysfunction, have a higher than normal AVO2 diff that becomes wider as exercise increases to 
compensate for the impaired cardiac output. (Shelton et al., 2010, Agostoni et al., 2000). 
Therefore at peak exercise even compensating for a greater exercise induced hypoxia would 
not explained the reduced AVO2 diff observed in PH patients.  
 Further studies are warranted in understanding the mechanisms affecting peripheral oxygen 
extraction during exercise in pulmonary hypertension.  
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The mean score in the FSS scale suggests PH patients suffer from a high degree of fatigue and 
higher than literature reported values for healthy subjects. (Valko et al., 2008) Fatigue scores 
correlated strongly with PH specific patient-reported quality of life scores. Peak peripheral 
oxygen extraction values negatively correlates with fatigue severity after adjustments for age- 
and gender- in PH patients and was the only measured exercise parameter to do so. Fatigue is 
a concept with multidimensional components that is recognized by the World Health 
Organization to have profound effect on patients secondary to the disease. (de Vries et al., 
2010) Studies have shown fatigue to be disabling symptom in chronic disease resulting in 
lower activity and engagement of patients. (de Vries et al., 2010) Fatigue is a common 
compliant among patients with PH. The observed association between fatigue and peripheral 
oxygen extraction is clearly in a small number of patients and further research is needed to 
confirm these preliminary findings. Nevertheless in chronic fatigue syndrome sufferers, 
peripheral oxygen extraction has been shown to be reduced compared to healthy participants 
with normal central cardiac response at peak exercise. (Vermeulen and Vermeulen van Eck, 
2014) Importantly, peripheral muscle fatigue can be due impaired convective oxygen delivery 
leading to accumulation of metabolites generated through oxygen-independent energy 
pathways affecting electrical-contraction coupling performance in the skeletal muscle.(Amann 
and Calbet, 2008) Although objectively measured skeletal muscle fatigue is not the same as 
patient-reported fatigue levels affecting exercise performance, however, it is noticeable that 
10-weeks of aerobic exercise training in PH is associated with reduced self-reported fatigue 
levels in patients.(Weinstein et al., 2013a) . Using 31P-MRS, in a small number of PH 
patients there is preliminary evidence of abnormal peripheral acid handling during exercise 
and this may contribute to skeletal muscle fatigue during exercise. (Chapter 3) Further 
mechanistic studies are needed to carefully dissect out the pathophysiology of fatigue 
affecting PH patients in order to achieve improved quality of life beyond what can be 
achieved through pharmacology  
 
5.5 Limitations 
There are a number of limitations to the study. The numbers of subjects was relatively small, 
with certain CPEX exercise parameters being available in only 14 control subjects. There 
were no available haemoglobin values for the control subjects although they were healthy 
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patients with no symptoms to suggest anaemia. The PH population were heterogeneous in 
terms of their underlying aetiologies, with potential variations in cardiac and pulmonary 
physiology affecting exercise performance. This however reflects real-world experience.   The 
effect of exercise induced arterial hypoxaemia on AVO2 diff could not be measured due to the 
non-invasive nature of the study. AVO2diff can be measured directly during maximum 
upright exercise with placement of a right heart catheter and a radial arterial line. Therefore, 
serial measurements of arterial and venous samples during exercise measuring haemoglobin 
content, oxygen saturations and partial pressures would allow for more definitive 
understanding of the limitations to exercise in patients with pulmonary hypertension. 
However, invasive procedures have their inherent limitations including the risks of bleeding, 
infection and trauma to underlying structures. A number of the PH subjects (n = 12) were on 
anticoagulation as part of their treatment. Further, the presumption was made that during peak 
exercise, the majority of blood flow is diverted to the skeletal muscle and therefore, AVO2 
diff is influenced predominantly due to skeletal muscle oxygen extraction.  
The study includes four patients with pulmonary arterial hypertension secondary to congenital 
heart disease. The use of non-invasive technology to assess cardiac output and intracardiac 
shunting affecting peak VO2 could potentially be a limiting factor in the interpretation of the 
results. In paediatrics, the potential for NICOM as a more accurate way of measuring cardiac 
output than echocardiography in congenital heart disease is being explored as the technology 
is dependent on pulsatile blood flow causing phase shift in the current.(Sun et al., 2015) The 
use of NICOM has been shown to have good correlation with cardiac output assessed at rest 
during paediatric cardiac surgery in patients with congenital heart disease in comparison to 
Fick method. (Tirotta et al., 2017) In subgroup analysis of the 14 PH patients without 
congenital heart disease compared to controls, at peak exercise, there was significantly 
reduced peak cardiac output (11.5 ± 4.3 vs 18.3 ± 5.5 L/min, p = 0.001) and peripheral 
oxygen extraction (9.6 ± 2.4 vs 12.9 ± 4.6 mL/dL, p = 0.021). The percentage change from 
rest to peak in peripheral oxygen extraction remained significantly reduced in PH compared to 
control subjects (170 ± 71 vs 87± 65 %, p = 0.002). Fatigue severity adjusted for age and 
gender remained negatively correlated with AVO2 diff (r = -0.679, p = 0.015). These findings 
suggest the inclusion of patients with congenital heart disease do not have bearing on the 
statistical findings of the study and would not affect the conclusions of the study.  
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5.6 Clinical Perspective 
The study has a number of important implications for clinical practice. There needs to be a 
paradigm shift away from assessing resting cardiopulmonary haemodynamics to those that 
can be measured with exercise. Further, non-invasive cardiac output measurements have a 
number of important advantageous.  Non-invasive technologies allow for the assessment of 
cardiac output with CPEX testing on an outpatient basis. Therefore it can be performed in 
selected patients within the clinic setting, prior to consideration of escalation of treatment. 
Right heart catheterisations (RHC) in most PH centres in the UK are only able to assess 
resting cardiopulmonary haemodynamic. Moreover, RHC carries inherent procedural risks 
with the procedure, as well as needing inpatient stay and monitoring after completion. CPEX 
on other hand, on maximum exercise in PH patients is relatively safe if the patient is 
adequately monitored. (Eloara V.M. Ferreira et al., 2016) The measurement of cardiac output 
in addition to conventional CPEX, would allow clinicians greater information in clinical 
decisions prior prescribing/escalating treatment that have significant cost-burden to the 
currently strained NHS budget.  
The study also shows that peripheral oxygen extraction is impaired in PH patients and 
associated with perceived fatigue levels. Further research is needed to confirm these findings 
but offers another avenue to focus in order to improve exercise tolerance beyond cardiac 
output. This supports the notion that PH is a multi-systemic disease and focusing on purely on 
improving cardiopulmonary haemodynamics would result in the under-treatment of the 
patient. In addition, it would seem there is a lack of appreciation that chronotropic 
incompetence during stress has an important and significant impact in limiting cardiac output 
on exercise. Therefore further research in understanding and importantly correcting this 
impairment would seem fundamental in improving exercise capacity. 
 
5.7 Conclusions 
The current study shows that aerobic exercise capacity is affected by central and peripheral 
limitations during maximal exercise in patients with pulmonary hypertension. From rest to 
peak exercise, cardiac output increases in proportion to change in oxygen uptake, but there is 
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no clear change in peripheral oxygen extraction with oxygen uptake in PH subjects as seen in 
healthy subjects. Finally, peak AVO2diff was the only exercise parameter to show association 
with patient-reported fatigue levels. Further carefully designed laboratory and clinical studies 
are needed to elucidate the mechanisms affecting peripheral oxygen extraction and fatigue in 
PH.  
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Chapter 6 Physical activity, Fatigue and Exercise capacity in Pulmonary 
Hypertension 
6.1 Introduction 
Pulmonary hypertension (PH) is a progressive debilitating condition leading to exercise 
intolerance, poor quality of life and premature death. (McLaughlin and McGoon, 2006) The 
last two decades has been marked by significant progress in the development of effective 
pharmacological targeted therapies that has revolutionised the management resulting in 
improved exercise capacity and survival. (Galie et al., 2013, Benza et al., 2012) Patients 
remain afflicted with symptoms that interferes with their daily activities and quality of life. 
(Mathai et al., 2016) Patients are assessed by monitoring their exercise capacity by 6 minute 
walk distance (6MWD), commonly used in many of the clinical drug trials in PH. 
(McLaughlin et al., 2009) Clinical assessments performed during hospital visits to monitor 
response to treatment and disease activity may not reflect real-world effect of the disease on 
the individual patient.  
Physical activity during daily living is increasingly recognised as an important marker of 
long-term cardiovascular health. (Crichton and Alkerwi, 2014) PH patients have a lower level 
of activity compared to controls and spend a greater proportion of their time in sedentary 
behaviour. (Pugh et al., 2012, Mainguy et al., 2011) Exercise training has shown self-reported 
activity scores increase in PH patients. (Weinstein et al., 2013a) Physical activity as a 
biomarker of clinical response to pharmacological intervention has not been assessed in PH 
patients. Furthermore, the trend in activity level over a period of time has not been studied. 
Accelerometers are the most commonly used method for the objective assessment of daily 
physical activity. The majority of these validated accelerometers measure daily energy 
expenditure or intensity of physical activity as measured by proprietary count. (Strath et al., 
2013) More recently, accelerometers can record raw acceleration expressed in gravity (g) 
units from three orthogonal axes. This allows for greater control over data processing and for 
comparison between different accelerometers to be made. (van Hees et al., 2013) 
Accelerometers are non-invasive, easy to wear devices that can accurately assess activity 
levels during daily life. (Pavey et al., 2016) 
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The primary aim of this pilot study is to determine the change in physical activity with the 
initiation or addition of PH-targeted treatment in comparison to current standard of objective 
exercise response by using the 6MWD at baseline, three and six-months. The secondary aims 
are 1) to determine the change in physical activity over period of six months, 2) assess the 
relationship between physical activity and exercise variables and 3) assess the correlation 
between fatigue, quality of life and activity levels. 
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6.2 Methods 
6.2.1 Study population 
Fifteen patients with PH were recruited from the National Pulmonary Hypertension Service 
(Newcastle) and who held a clinical diagnosis of pulmonary hypertension. Patients with a new 
diagnosis or required optimisation of targeted therapies who were able to exercise without any 
adverse response were approached. Patients with other significant cardiovascular, pulmonary 
or peripheral comorbidities were excluded. The study was approved by the local regional 
ethics committee (Westminister - 15/LO/0144) and all participants provided written informed 
consent to participate in the study  
All patients at baseline and three months following treatment change underwent baseline 
exercise capacity assessment by use of 6 minutes’ walk distance (6MWD), cardiopulmonary 
exercise testing (CPEX) ± with non-invasive haemodynamic measurement, wearing a 
physical activity monitor, and completion of two questionnaires. All patients had their World 
Health Organization functional class (WHO FC) assigned and N-terminal pro-brain naturietic 
peptide (NT-proBNP) measured.  
 
6.2.2 Physical activity assessment 
Physical activity monitoring was undertaken by all participants at baseline, three and six 
months using a triaxial, raw accelerometer (GeneActiv, Unilever, UK) on their wrist 
continuously for 5-7 days for at least 3 valid weekdays and 2 valid weekend days. Valid days 
were counted as wear time ≥ 16hours per day. (Charman et al., 2016) From the raw data, 
physical activity were deemed as the mean acceleration (millig) during the most active (ΔM5) 
and least active (ΔL5) five-hour period of each day and the difference between these periods 
(ΔM5L5). (Innerd et al., 2015) Daily sedentary - low and moderate-vigorous (MVPA) activity 
time from the acceleration was calculated based on metabolic equivalents (METS) from 
values derived from previous studies. (Hildebrand et al., 2014) 
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6.2.3 Exercise capacity assessment 
Each participant with pulmonary hypertension completed symptom-limited CPEX testing 
using a step-protocol with breath-by-breath gas analysis performed at rest and during exercise 
(Medgraphics, St Paul, MN, USA) to measure oxygen consumption. Simultaneously with gas-
exchange, central haemodynamic variables were measured at rest and during CPEX using the 
bioreactance method (NICOM®, Cheetah Medical, USA).  
Peak VO2 was highest O2 uptake, averaged over last 30 seconds of exercise.  Arterio-venous 
oxygen content difference, AVO2 diff was obtained indirectly using the Fick method as the 
ratio between oxygen consumption and cardiac output. Maximum predicted heart rate was 
defined as 220 minus age in years.  
6.2.4 Fatigue severity and quality of life 
Each participant completed two questionnaires being fatigue severity scale (FSS) and quality 
of life (emPHasis-10) prior to exercise testing. 
6.2.5 Statistical analysis 
Analysis was performed using SPSS software package version 22 (Chicago, IL). All 
continuous data is presented as mean ± standard deviation. Normality of data was determined 
by Shapiro-Wilk test. Parameteric data analysed by paired sample T test and non-parametric 
data analysed by Wilcoxon signed rank test. Categorical data analysed using Fisher’s exact 
test. Correlation was assessed either Pearson or Spearman testing. A p-value less than 0.05 
was considered significant.  
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6.3 Results 
6.3.1 Population characteristics 
The baseline clinical characteristics of the 15 participants are provided in Table 9.  
Table 9: Baseline Characteristics 
 Patients 
Age (years) 58 ± 15 
Gender (M:F) 5 :10 
Height (cm) 165 ± 10 
Weight (kg) 68 ± 14 
BSA (m2) 1.76 ± 0.22 
PH subtype 
- IPAH 
- PoPH 
- PAH-CHD 
- CTEPH 
 
8 
1 
5 
1 
WHO FC 
- II 
- III 
 
3 
12 
NT-proBNP, pg/ml 
 
892 ± 1015 
Haemoglobin (gm/dL) 
 
14.2 ± 1.0 
Haemodynamics§ 
- mPAP (mmHg) 
- sPAP (mmHg) 
- RAP (mmHg) 
- PCWP (mmHg) 
- PVR (Woods) 
- CO (L/min) 
- CI (L/min/m2) 
- SvO2, % 
 
42 ± 11 
73 ± 24 
4 ± 3 
6 ± 4 
9.7 ± 4.3 
4.2 ± 1.2 
2.4 ± 0.8 
65 ± 8 
 
Baseline Treatment 
- PDE5i 
- PDE5i and ERA 
- No Therapy 
 
 
8 
3 
4 
Change in Treatment 
- Initiated PDE5i 
- Added ERA to existing PDE5i therapy† 
- Switched ERA§ 
 
4 
8 
3 
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Abbreviations:  BSA – body surface area, IPAH – idiopathic pulmonary arterial hypertension, 
PoPH – portopulmonary hypertension, PAH-CHD – Pulmonary arterial hypertension 
secondary to congenital heart disease, CTEPH – chronic thromboembolic pulmonary 
hypertension, WHO FC – World Health Organization Functional class, NT-proBNP – N-
terminal pro Brain Naturietic peptide, mPAP – mean pulmonary arterial pressure, sPAP –
systolic pulmonary arterial pressure, RAP – right atrial pressure, PVR – pulmonary vascular 
resistance, CO – cardiac output, CI – cardiac index, SvO2- mixed venous oxygen saturation, 
PDE5i – phosphodiesterase type 5 inhibitor, ERA – endothelin receptor antagonist  
§ - switched from bosentan to macitentan † - macitentan was added to sildenafil 
 
6.3.2 Physical activity and adherence 
Fifteen patients wore the wrist-based activity monitor continuously for at least 5 days with 
only one patient failing to wear the monitor for the more than 16 hours a day. Therefore, the 
patient’s results were removed from the final analysis. No patient reported adverse effects or 
discomfort with only one patient reporting the activity monitor was a nuisance. The average 
valid days per patient at baseline 7.2 ± 1.2 days, 3 months 8.5 ± 2.4 days and 6 months 13.3 ± 
1.9 days. At baseline, time spent in MVPA on the weekday was 77 ± 73 and weekend 72 ± 64 
minutes. At three months, time spend in MVPA on the weekday was 84 ± 76 and weekend 80 
± 76 minutes. There was strong correlation between baseline and three months in time spend 
in MVPA on weekday (r = 0.927, p < 0.001) and weekend (r = 0.959, p <0.001).    
 
6.3.3 Change in exercise capacity and physical activity with treatment 
From baseline to three months, 6MWD increased significantly by 41 ± 37 m (p = 0.001), with 
significant improvement in WHO FC (2.8 vs 2.2, p < 0.001) and non-significant improvement 
in NT-proBNP (1015 ± 262 vs 584 ± 151 pg/ml, p = 0.336). In terms of physical activity, we 
noted no significant change in the most active 5 hours, least active 5 hours or the difference 
between them (ΔM5L5), with no significant change in time spend in sedentary activities. 
(Table 10) There was no correlation between Δ6MWD and ΔM5L5 (r = 0.393, p = 0.147) or 
ΔMVPA (r = -0.236, p = 0.398) from baseline to 3 months. The ΔM5L5 and time spend in 
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MVPA remained consistent with strong correlation between baseline, 3 and 6 month 
suggesting activity levels over this period of time in individual PH patients did not change. 
Figure 22 shows time spend in at different activity levels at the three time points categorised 
by acceleration in mg.  
Table 10: Activity level classification at the three time points 
 Baseline 3 months 6 months 
Rest/active analysis (millig) 
Mean ENMO 
M5 
L5 
ΔM5L5 
 
23 ± 10 
42 ± 19 
5 ± 1 
38 ± 18 
 
24 ± 11 
46 ± 19 
4 ± 1 
41 ± 68 
 
22 ± 19 
41 ± 22 
5 ± 1 
36 ± 22 
Activity intensity classification 
(min/day) 
PAsedentary/low 
PAmod/high (MVPA) 
 
 
1364 ± 70 
74 ± 68 
 
 
1357 ± 76 
82 ± 58 
 
 
1369 ± 73 
70 ± 70 
Abbreviations: ENMO – Enclidean Norm Minus One, M5- most active five hours ENMO 
value, L5 – least active 5 hours ENMO value, PA – physical activity 
 
6.3.4 Exercise capacity and physical activity 
The study determined whether there was any correlation between current measures of exercise 
capacity and physical activity. There was no correlation between mean ENMO, ΔM5L5 or 
time spend in MVPA and peak oxygen uptake (VO2), cardiac output, cardiac index or AVO2 
diff. There was a negative correlation between age and physical activity: mean ENMO (r = -
0.539, p = 0.038) ΔM5L5 (r = -0.600, p = 0.018) and time in MVPA (r = -0.618, p = 0.014). 
There was no significant difference between the genders (M vs F) in terms of ΔM5L5 (27 ±10 
vs 43 ± 19, p = 0.108) and MVPA (1407 ± 23 vs 1343 ± 76, p = 0.092), with no significant 
difference in age between the genders.  
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6.3.5 Quality of life, fatigue and physical activity 
Patient reported quality of life scores did not correlate with any parameter of physical activity 
including ΔM5L5 (r = -0.279, p = 0.371) and time in MVPA (r = -0.162, p = 0.565). Fatigue 
severity scores also did not correlate with any parameter of physical activity including 
ΔM5L5 (r = -0.170, p = 0.544) and time in MVPA (r = -0.162, p = 0.565). Fatigue severity 
demonstrated non-significant decrease from baseline to three months (4.1 ± 1.4 vs 3.8 ± 1.3, p 
= 0.149). There was no correlation between Δ6MWD and ΔFSS score (r = -0.127, p = 0.651). 
(FiFigure 24) There was no correlation between individual itemized effect of fatigue on 
motivation, physical function and activities of daily living and any marker of physical activity 
measured objectively. 
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Figure 22: Acceleration categories according to three time points.  
Data are Mean ± SD. 
 
108 
 
Figure 23: Graphical representations of the change in 6MWD and change in time spend 
in moderate to vigorous physical activity in minutes from baseline to three months.  
(R2 = 0.154) 
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Figure 24: Graphical representation of change in 6MWD and change in fatigue severity 
score with treatment at three months.  
(R2 = 0.03) 
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6.4 Discussion 
In this pilot study, objective raw accelerometry data was collected over a period of six 
months in patients with pulmonary hypertension who underwent initiation or change in their 
targeted treatment. The study showed 1) there was no change in daily physical activity 
despite significant improvement in 6MWD from baseline to three months, 2) daily physical 
activity did not correlate with exercise and haemodynamic variables, 3) patient-reported 
quality of life and fatigue severity scores had no bearing on daily physical activity level and 
4) physical activity level remains consistent without significant fluctuations over a period of 
six months. The study has shown preliminary evidence that pharmacological treatment for 
PH leading to improvement in exercise capacity does not result in change in daily physical 
activity. Furthermore, daily physical activity does not correlate with measured self-reported 
fatigue scores, exercise and haemodynamic variables. 
The study showed no change in activity levels in acceleration measured in millig from 
baseline to three months after initiation or change of treatment in targeted therapies. In this 
current study, raw accelerometery data was collected using wrist-worn devices allowing for 
greater control over the processing of the information by the user. The activity change was 
compared with currently accepted clinical biomarkers of disease severity where at three 
months there were significant improvements noted in WHO FC and 6MWD. Activity levels 
remained consistent and unchanged throughout the six month period. Furthermore, at 
baseline and three months, activity levels did not correlate with 6MWD. These preliminary 
results suggest habitual daily activity were not altered by pharmacological intervention in 
pulmonary hypertension. 
Physical activity is a result of complex interaction of health, social and behavioural factors 
affecting daily function. There has been extensive research into physical activity in ischaemic 
heart disease, left ventricular failure and COPD. (Schonmann et al., 2015, Spruit et al., 2015, 
Backshall et al., 2015, Echouffo-Tcheugui et al., 2015) Research has focused on exercise 
intervention and increasing the proportion of daily time undertaking moderate-vigorous 
physical activity. In pulmonary hypertension, exercise training has been shown to be 
beneficial in terms of improving exercise capacity, quality of life and fatigue. (Mereles et al., 
2006, Weinstein et al., 2013b) Whilst supervised exercise training in selected population with 
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PH is clearly beneficial, trying to improve daily physical activity level in the long term in 
patients with essentially a chronic disease affecting their daily life has received limited 
attention. 
Using accelerometer that generates proprietary counts (steps per day), have shown that 
subjects with PH compared to healthy controls have less activity level in terms steps taken 
per day and spend greater proportion of their day undertaking sedentary activity. (Pugh et al., 
2012) These studies also demonstrated daily physical activity correlated with WHO FC and 
6MWD. (Mainguy et al., 2011, Pugh et al., 2012) There has been no study regarding the 
prognostic impact of low activity levels in PH or whether exercise intervention does lead to 
increase in long-term daily activity levels. 
In the study, 6MWD distance improved with treatment, whilst daily physical activity levels 
demonstrated no such response. The 6MWD is the current accepted biomarker of exercise 
capacity along with clinical assessment to assess the effect of treatment on individual 
patients. Until recently, almost all drug trials involving PH have used the 6MWD as the 
primary outcome measure of effectiveness. The reason for the common use of the 6MWD is 
the low-cost, reproducibility and the ability to be performed by all centres involved in the 
care of PH patients by personnel without the requirement of significant experience. 
Maintaining an appropriate 6MWD has been associated with long-term survival.(Sitbon et al., 
2002, Barst et al., 1996) Objectively measuring physical activity relays the real-world effect 
of the disease on the individual patient that is not reflected in submaximal exercise testing or 
clinical assessment. The 6MWD test has its inherent limitations including failing to adjust for 
the height of the patient, and the ceiling effect. (Gaine and Simonneau, 2013) Recently 
published multicentre clinical drug trials in PH, have moved away from the 6MWD and used 
the occurrence of clinical events as the primary outcome measure. (Pulido et al., 2013, Galie 
et al., 2015) The question arises as to whether measured daily activity levels reflects a better 
biomarker encompassing multi-dimensional factors that may reflect future clinical events and 
long-term prognosis in pulmonary hypertension is unclear. In COPD, low physical activity 
has been shown as independent factor associated with mortality and maintaining a high level 
of physical activity is associated with survival. (Waschki et al., 2011, Vaes et al., 2014) 
Physical activity is influenced by other factors beyond exercise tolerance including the effect 
of co-morbidities and increasing age, both of which are increasingly recognised and dominate 
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the cohort of patients seen with PH in the modern era. (Ling et al., 2012) In the current study, 
age is significant factor negatively associated with activity levels, therefore addressing the 
needs of the aging PH population is an important factor to consider and how best to keep 
them as active as possible is clearly an important subject. 
The study analysed the effect of PH-targeted treatments on quality of life (emPHasis-10) and 
fatigue severity. Pharmacological treatment of PH failed to show any significant effect on 
both quality of life and fatigue severity in the present study. This may simply reflect the lack 
of adequate study power to detect to such a significant difference to both patient-reported 
questionnaires. At baseline, fatigue effect on daily and physical functioning did not correlate 
with any marker of activity levels. Mental and physical fatigue levels correlated with day-to-
day variability in physical activity levels in a recent study of 15 patients with IPAH. (Matura 
et al., 2016) The authors also showed relationship between activity bouts and energy levels, 
although the current study failed to demonstrate such an association. (Matura et al., 2016) 
There is considerable difference between the study designs, including different questionnaires 
used to assess fatigue and QoL, with different accelerometer with differing final markers of 
activity levels. Furthermore, both studies enrolled relatively small number of patients (n = 
15). The interrelationship between subjective symptoms and objectively measured activity 
levels in PH patients’ needs further study, as our understanding of this area remains poor. 
Whilst the focus of recent clinical trials in PH has been on long-term morbidity and mortality 
outcomes, real-world clinical practice is focused in improving the symptoms and QoL on an 
individual basis. Many of these symptoms are beyond the reach of existing targeted therapies 
and therefore, how best to address these issues pertaining to patients with PH needs to be 
considered on an individual basis. 
 
6.5 Limitations 
The present pilot study is not without limitation. This is a pilot single-centre study, with a 
small number of participants, with a wide range of diagnosis, age and gender. The lack of 
improvement in activity levels with treatment and the absence of correlation of activity with 
peak exercise variables maybe due to the size of the study. Age as demonstrated in our study 
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has an impact on activity levels. There may be differing factors involved in improving 
habitual physical activity levels of patients of different age groups and gender beyond 
treatment of their pulmonary hypertension. Whilst our inclusion and exclusion criteria was 
far less restrictive than in multicentre randomised, placebo-controlled pharmaceutical drug 
trials in PH, the study population does reflect modern clinical practice in pulmonary 
hypertension in the United Kingdom. There was no control group to compare activity levels 
with PH subjects, however, that was not the aim of the study and has been previously 
undertaken by other authors. There was limited consideration of other factors that may affect 
activity levels including social circumstances, depression, anxiety and motivation levels. No 
one patient was taking medications for depression or anxiety. Currently the delineation 
between sedentary and low activity levels has not been clearly defined using the GenieActiv® 
monitor; therefore we cannot see a change from sedentary to low activity levels with 
treatment. In our population, reducing the time spend in sedentary behaviour and increasing 
the time in low  rather than in  moderate-vigorous physical activity is a more plausible 
response to intervention. Furthermore, minimum change in activity levels that reflects 
meaningful clinical benefit in patients with chronic disease has not been investigated using 
raw accelerometer data. 
 
6.6 Clinical Perspective 
The study failed to show any consistent improvement in habitual physical activity with 
treatment despite improvement in other accepted clinical and biochemical biomarkers. 
Therefore alternative ways to improve activity levels in PH patients is needed beyond 
pharmacological therapy. Exercise rehabilitation with an educational component to increase 
activity levels and improve symptoms is a possibility that could address some of the needs of 
PH patients. The recent European Society of Cardiology guidelines recommend aerobic 
exercise training under supervision in selected PH patients. (Galie et al., 2016) Exercise 
training improves exercise capacity, cardiopulmonary haemodynamics and quality of life. 
(Grunig et al., 2012a, Ehlken et al., 2016, Yuan et al., 2015) Potentially, exercise could help 
to reduce perceived fatigue levels and increase activity levels. (Weinstein et al., 2013b) 
Further research is needed, in order develop exercise programmes that could be tailored to 
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individual needs that is both safe and efficacious to be undertaken locally or at home, without 
the requirement for inpatient stays that was a requisite for many of the studies on exercise 
training in PH. From the chronic obstructive pulmonary disease pulmonary rehabilitation 
studies, it should be noted that patients fail to maintain their activity levels in their home 
environment after the sessions finishes. Current financial and resource limitations within the 
National Health Service would mean inpatient stays for exercise training wouldn’t be feasible 
beyond the remit of research. Therefore, the focus should be on research that can be initiated 
and monitored within the outpatient setting.  
There has been a significant shift in the last 20 years to improve physical activity in the 
general population. Strategies to improve daily physical activity in PH patients may be more 
successful than in the general population due to their frequent interaction with health care 
professionals. This maybe include the monitoring physical activity at home with commonly 
available accelerometers, continuous education providing reinforcement and further research 
to understand prognosis as a result of  differing activity levels but well defined 
patients.(Tuso, 2015) 
 
6.7 Conclusions 
This pilot study shows that objectively measured daily physical activity do not change to 
reflect changes in exercise capacity or WHO FC with treatment. Activity levels remained 
consistent throughout the study period of six months, with no correlation with fatigue or QoL 
scores. Activity levels did not correlate with variables of maximum exercise testing. Further 
larger studies are needed into first validating accepted measurements of activity levels and 
patient-reported fatigue severity questionnaires in PH. This can be used in order to investigate 
different interventions to address daily physical activity and perceived fatigue by patients. 
However, data from this pilot study suggest that clinical care teams and research investigators 
should be aware of the decoupling of physical capacity (6MWT) and physical function 
(everyday physical activity) in therapeutic trials in PH.  
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Chapter 7 General Discussion 
The work presented in this thesis attempts to further our understanding of the role of skeletal 
muscle function, peripheral oxygen extraction and habitual physical activity in PH. This has 
included the application of 31P-MRS to assess ex-vivo skeletal muscle bioenergetics, skeletal 
muscle biopsy to determine in vitro mitochondrial function, peripheral oxygen extraction 
limitations to maximal exercise capacity and the effect of targeted therapy on habitual daily 
physical activity levels. PAH is a rare, heterogeneous disease with varying aetiologies, where 
individual patients present to clinical service at differing stages of severity. Developing 
treatments acting beyond the pulmonary vasculature is important as we begin to understand 
the concept of PAH being a multi-systemic disease. Recent studies have demonstrated 
convincing evidence of the benefits of exercise training for improving aerobic exercise 
capacity and quality of life in stable patients established on targeted therapies. In order to 
understand further the limitations to exercise, basic science and clinical studies were 
undertaken. 
Assessing skeletal muscle bioenergetics and ex-vivo mitochondrial function to stress 
(exercise) is important in determining altered energy generation and acid handling. Chapter 3 
uses 31P-MRS in a pilot study of six patients with idiopathic pulmonary arterial hypertension. 
There have not been any previous studies employing 31P-MRS to assess skeletal bioenergetics 
in PAH. From spectroscopy analysis and compared to healthy control values, there was 
evidence of an increase in the time taken for phosphocreatine recovery. This effect is most 
likely due to limitations of oxygen delivery as a result of the underlying PAH physiology 
rather than skeletal muscle mitochondrial dysfunction. There was no decrease in the time of 
pH recovery to suggest rapid proton efflux, further supporting the evidence against 
mitochondrial dysfunction. The results of this study indicate normal skeletal muscle 
mitochondrial function in PH. 
There was a preliminary signal of altered muscle acid handling during exercise with 
significantly lower pH during exercise and increase in pH recovery times. Altered peripheral 
muscle acid handling is associated with perceived fatigue levels in other chronic conditions 
such primary biliary cirrhosis, with links to autonomic function controlling the sodium/proton 
antiporters. There is some published evidence of impaired autonomic function in PAH and 
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the question arises as to whether this could affect muscle acid handling leading to fatigue so 
commonly reported by patients on exertion. This would require carefully considered basic 
clinical studies to determine if autonomic dysfunction has a significant effect on acid 
handling in PH in the skeletal muscle. Furthermore, what is the role of altered acid handling 
has on the development of muscle fatigue and exercise limitation in PAH remains 
unexplained.  
In order to corroborate the results from 31P-MRS, in chapter 4 in vitro analysis of skeletal 
muscle mitochondrial oxidative phosphorylation protein abundance and function using 
established and state-of-the-art techniques were undertaken. Quadruple immunofluorescence 
(QF) allows for assessment OXPHOS subunit expression and abundance within each 
individual myofibre with adjustment for mitochondrial-mass.  Histochemistry showed normal 
complex II and complex IV function using a more subjective approach, whilst QF showed 
consistently normal complex I and IV subunit protein abundance after adjustment for 
mitochondrial mass. These results support the findings from chapter 3 that intrinsic 
mitochondrial function in the skeletal muscle of PAH patients’ is normal, and therefore do 
not limit exercise capacity.   
There are certainly changes within the skeletal muscle in PAH patients that may contribute to 
fatigue and difficulties of performing everyday tasks. This includes decrease in type 1 fibre 
expression, capillary to muscle fibre ratio, imbalance between pathways related to muscle 
protein atrophy and synthesis as well as altered intrinsic muscle contractility. These changes 
have an impact on functional assessments as evident by a decrease in muscle strength and 
correlation with exercise capacity. There are many studies within the literature to support the 
role of exercise training in improving exercise tolerance. Out of these, only one randomised 
study so far supports the notion that exercise can help to stem and reverse the skeletal muscle 
changes by increasing the expression of oxidative enzymes and muscle capillarity in PAH. 
All studies involving analysis of muscle biopsies are limited by small number of participants. 
This is inevitable due to the strict inclusion criteria to avoid patients with confounding co-
morbid conditions as well as the invasive nature of the study prohibiting the recruitment of 
patients. 
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The impairments to exercise in PAH are evidently upstream from skeletal muscle 
mitochondria. Therefore factors affecting oxygen delivery to the exercising skeletal muscle 
needs further clarification, including the role of impaired cardiac output and peripheral 
oxygen extraction. Significant focus of research in PAH has been on the right ventricle 
adaptation to chronic pressure overload. There has been some research to assess cardiac 
output using right heart catheterisation and supine exercise testing. This has its inherent 
limitations of failure to recruit and exercise to maximal performance using large muscle mass 
that is representative of everyday living. Non-invasive haemodynamic monitoring allows for 
cardiac output to be measured continuously and in conjunction with oxygen uptake during 
cardiopulmonary exercise testing. Therefore, allowing for an indirect assessment of 
peripheral oxygen extraction using Fick principle at maximum exercise.  
Chapter 5 demonstrates evidence of impaired chronotropic response and peripheral oxygen 
extraction due to maximal upright exercise. Whilst cardiac output in response to exercise 
does improve in response to treatment and exercise training in PAH, limited work has been 
undertaken as to whether peripheral oxygen extraction has a significant role in limiting 
exercise. The reasoning for the impaired peripheral oxygen extraction would require a greater 
understanding of the pathophysiology including the role of autonomic function, oxygen 
diffusion capacity and perfusive oxygen delivery in the peripheries of PAH patients. The non-
invasive nature of the current study does limit our interpretation due to the inability to 
accurately assess partial pressure of oxygen and exercise induced desaturation during testing.  
To study the role of blood flow, blood pressure, and temperature to the peripheral muscle 
mass during exercise can be achieved through the use of femoral arterial and venous lines but 
recruitment into such studies maybe difficult even on the assumption that ethical approval is 
obtained. However, this would allow for a greater understanding of the factors affecting 
peripheral limitations to exercise in PAH. Whilst such invasive tests cannot be undertaken in 
routine clinical practice, developing the role of non-invasive methods to assess central 
haemodynamics in response to treatment is important. The NICOM® technology is easy to 
use and validated to assess cardiac output during cardiopulmonary exercise testing, therefore 
could be transferred into routine clinical practice pending clear evidence of benefit in the 
management of patients. 
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Finally, Chapter 6 assesses the effect of targeted PAH treatment on daily activity levels using 
raw accelerometer data. This pilot study demonstrates a lack of significant effect of targeted 
treatment on activity levels and shifting patients from sedentary to low and moderate-
vigorous activity levels. Leading an active lifestyle has come to be recognised as an 
important factor in the overall health of a person. Whilst there are many factors affecting 
activity, PAH patients have reduced activity levels and spend proportionally greater amount 
of time performing sedentary tasks compared to controls. Changing this behaviour would 
seem unlikely with pharmaceutical agents. The study also showed a lack of treatment effect 
on patient-reported fatigue levels. The study has shown that in PAH, fatigue and quality of 
life are closely correlated, therefore treatments to improve fatigue in PAH patients would 
seem appropriate. To achieve such a desired effect education and regular exercise training are 
potential ways to address both physical inactivity and fatigue. Clearly further research is 
needed to prove that exercise can address fatigue and activity levels in a heterogeneous 
population with PAH that reflects everyday clinical practice. In addition any exercise 
prescription must be safe to be carried out without supervision in order to be realistically 
achievable in the long-term. 
In summary, this thesis increases our understanding to the limitations of exercise capacity in 
PAH beyond the pulmonary vasculature. Impaired oxygen delivery by means of diminished 
cardiac output no doubts plays a key role, but limited peripheral oxygen extraction could be a 
contributory mechanism. Current PAH therapies would seem ineffective to address factors 
such as fatigue and activity levels. Therefore, there is a fundamental need to develop 
alternative additional treatments to address symptoms of PAH to improve exercise capacity, 
fatigue and daily activity levels in order to achieve a more successful holistic management of 
patients with an incurable and life-limiting disease.  
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Chapter 8 Appendices 
8.1 Appendix A – Fatigue Questionnaire 
Date:                                                            Name:                 
 
Please circle the number between 1 and 7 which you feel best fits the following statements. This 
refers to your usual way of life within the last week. 1 indicates “strongly disagree” and 7 indicates 
“strongly agree.” 
 
Read and circle a number Strongly Disagree                                                    Strongly Agree 
1. Exercise brings on my 
fatigue. 
1              2                3                  4                  5                6                7 
2. I am easily fatigued. 
 
1              2                3                  4                  5                6                7 
3. Fatigue interferes with 
my physical 
functioning. 
1              2                3                  4                  5                6                7 
4. Fatigue causes 
frequent problems for 
me. 
1              2                3                  4                  5                6                7 
5. My fatigue prevents 
sustained physical 
functioning. 
1              2                3                  4                  5                6                7 
6. Fatigue interferes with 
carrying out certain 
duties and 
responsibilities. 
1              2                3                  4                  5                6                7 
7. Fatigue is among my 
most disabling 
symptoms. 
1              2                3                  4                  5                6                7 
8. Fatigue interferes with 
my work, family or 
social life. 
1              2                3                  4                  5                6                7 
9. My motivation is lower 
when I am fatigued 
1              2                3                  4                  5                6                7 
     
 
 
Total Score:          
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8.2 Appendix B – emPHasis-10 Questionnaire 
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8.3 Appendix C - Patient Consent Form Study  
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8.4 Appendix D – Patient Consent Form Study 2 
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